[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 7762
1. Koh H, Nakamae H, Koh KR, Ohsawa M, Nakane T, Takeoka Y, Aimoto R, Aimoto M, Wada-Inoue E, Terada Y, Yamane T, Hino M: Serum cytokine profiles at the onset of severe, diffuse alveolar hemorrhage complicating allogeneic hematopoietic stem cell transplantation, treated successfully with pulse intravenous cyclophosphamide. Acta Haematol; 2010;124(3):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 59-year-old man with lymphoma-type adult T-cell leukemia/lymphoma was admitted to hospital for treatment of a skin relapse on day 398 after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • To induce a graft-versus-adult T-cell leukemia/lymphoma effect, we discontinued methylprednisolone and tacrolimus.
  • About a month after the discontinuation, he developed grade II acute graft-versus-host disease (GVHD) with a high fever.
  • [MeSH-minor] Chemokines / blood. Graft vs Host Disease / etiology. Humans. Injections, Intravenous. Leukemia-Lymphoma, Adult T-Cell / therapy. Male. Middle Aged. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20938173.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Chemokines; 0 / Cytokines; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


2. Piccaluga PP, Martinelli G, Isidori A, Malagola M, Rondoni M, Paolini S, Amabile M, Iacobucci I, Baccarani M, Visani G: Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients. Leukemia; 2008 Aug;22(8):1617-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term molecular complete remission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients.
  • [MeSH-major] Interferon-alpha / therapeutic use. Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18273047.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


3. Leslie M, Case MC, Hall AG, Coulthard SA: Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia. Br J Haematol; 2006 Mar;132(6):740-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia.
  • L-asparaginase is active in the treatment of acute lymphoblastic leukaemia (ALL) through the depletion of serum asparagine.
  • Here we report that median asparagine synthetase (AS) mRNA levels were higher in acute myeloid leukaemia (AML) than ALL blasts in both children and adults, with intermediate levels in normal peripheral blood mononuclear cells (NPBMC).
  • [MeSH-major] Aspartate-Ammonia Ligase / analysis. Lymphocytes / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Cell Line, Tumor. Child. Child, Preschool. Female. Humans. Infant. Leukemia, Myeloid / enzymology. Leukocytes, Mononuclear / enzymology. Male. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487174.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  •  go-up   go-down


Advertisement
4. Sashida G, Bazzoli E, Menendez S, Liu Y, Nimer SD: The oncogenic role of the ETS transcription factors MEF and ERG. Cell Cycle; 2010 Sep 1;9(17):3457-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MEF cooperates in tumorigenesis in retroviral insertional mutagenesis-based mouse models of cancer and MEF is overexpressed in human lymphoma and ovarian cancer tissues via unknown mechanisms.
  • ERG (Ets related gene) overexpression or increased activity has been found in various human cancers, including sarcomas, acute myeloid leukemia and prostate cancer, where the ERG gene is rearranged due to chromosomal translocations.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2498-505 [15961513.001]
  • [Cites] Leuk Res. 2006 Aug;30(8):1037-42 [16303180.001]
  • [Cites] Oncogene. 2007 Jun 7;26(27):4032-7 [17213815.001]
  • [Cites] Nat Immunol. 2008 Jul;9(7):810-9 [18500345.001]
  • [Cites] Nat Rev Cancer. 2008 Jul;8(7):497-511 [18563191.001]
  • [Cites] Cell Stem Cell. 2009 Jan 9;4(1):37-48 [19128791.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3337-47 [19168790.001]
  • [Cites] Mol Cell Biol. 2009 Jul;29(13):3687-99 [19380490.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12465-70 [19592505.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):153-9 [12185366.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):160-5 [12185367.001]
  • [Cites] Immunity. 2002 Oct;17(4):437-49 [12387738.001]
  • [Cites] Leuk Res. 2003 May;27(5):387-92 [12620289.001]
  • [Cites] Blood Cells Mol Dis. 2003 Nov-Dec;31(3):342-50 [14636650.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1721-9 [8895518.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8239-44 [9653171.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3635-44 [10207087.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9234-42 [16275934.001]
  • (PMID = 20814243.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK052208
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / ELF4 protein, human; 0 / ERG protein, human; 0 / Proto-Oncogene Proteins c-ets; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; EC 3.6.5.2 / ras Proteins; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC3230474
  •  go-up   go-down


5. Wang YR, Jin RM, Xu JW, Xiao Y, Zhou DF, Zhang ZQ: Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia. Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb;10(1):1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
  • OBJECTIVE: The ALL-XH-99 protocol for the treatment of childhood acute lymphoblastic leukemia (ALL) has been performed in the Union Hospital for 10 years.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


6. Usvasalo A, Savola S, Räty R, Vettenranta K, Harila-Saari A, Koistinen P, Savolainen ER, Elonen E, Saarinen-Pihkala UM, Knuutila S: CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study. Leuk Res; 2008 Aug;32(8):1228-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study.
  • [MeSH-major] Genes, p16. Oligonucleotide Array Sequence Analysis / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Sequence Deletion

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18328560.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


7. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema NA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, Grever MR: The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood; 2009 May 7;113(19):4656-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
  • Therapeutic options for advanced B-cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) are limited.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Oct;17(10):1981-9 [14513048.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60 [12011454.001]
  • [Cites] J Org Chem. 2004 May 14;69(10):3350-8 [15132542.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1177-84 [12149195.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44791-800 [12237314.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1466-71 [12697868.001]
  • [Cites] Blood. 2003 Jul 15;102(2):652-8 [12649137.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):367-74 [12663328.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 15;417(2):141-52 [12941295.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jun;50(3):223-61 [15182827.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26915-21 [15078892.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1207-14 [15116122.001]
  • [Cites] Anticancer Res. 1988 May-Jun;8(3):355-67 [3389740.001]
  • [Cites] J Natl Cancer Inst. 1991 Jun 5;83(11):757-66 [2041050.001]
  • [Cites] J Cell Physiol. 1996 Mar;166(3):523-36 [8600156.001]
  • [Cites] Antiviral Res. 1995 Nov;28(3):265-79 [8629818.001]
  • [Cites] J Nat Prod. 1997 Jun;60(6):606-8 [9214732.001]
  • [Cites] Z Naturforsch C. 1999 Jan-Feb;54(1-2):55-60 [10223787.001]
  • [Cites] J Immunol Methods. 2004 Nov;294(1-2):15-22 [15604012.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1259-62 [15467463.001]
  • [Cites] Immunology. 2005 Apr;114(4):441-9 [15804279.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7075-84 [15905551.001]
  • [Cites] Blood. 2005 Jul 15;106(2):408-18 [15797997.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2513-9 [15972445.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):240-9 [16616071.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3978-80 [16618714.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1419-21 [16645636.001]
  • [Cites] Anticancer Agents Med Chem. 2006 Jul;6(4):319-45 [16842234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11713-8 [16864779.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1334-8 [16670263.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3349-56 [17094452.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2008-13 [17068155.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Expert Opin Emerg Drugs. 2007 Mar;12(1):165-79 [17355221.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2144-50 [17404098.001]
  • [Cites] J Biol Chem. 2007 Aug 3;282(31):22551-62 [17553788.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4B):2175-83 [17695501.001]
  • [Cites] Cell Death Differ. 2007 Sep;14(9):1576-82 [17612585.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1839-46 [17565740.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(41):7831-4 [17806093.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(41):7835-8 [17823902.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3190-9 [18192508.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2651-60 [18551192.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3807-17 [18599795.001]
  • [Cites] J Am Chem Soc. 2009 Feb 4;131(4):1607-16 [19140688.001]
  • [Cites] Z Naturforsch C. 1999 Dec;54(12):1075-83 [10685499.001]
  • [Cites] Blood. 2000 Jul 15;96(2):393-7 [10887097.001]
  • [Cites] Biotechniques. 2001 Sep;31(3):464, 466 [11570486.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23):6627-36 [11726499.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1885-93 [11877256.001]
  • [Cites] Leukemia. 2002 Apr;16(4):444-54 [11960321.001]
  • [Cites] Blood. 2004 May 1;103(9):3278-81 [14726385.001]
  • (PMID = 19190247.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U19 CA052956; United States / NCI NIH HHS / CA / P01CA125066; United States / NCI NIH HHS / CA / P01 CA125066; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / CA52956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mcl1 protein, mouse; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0 / Tcl1 protein, mouse; 0 / Triterpenes; 0 / silvestrol
  • [Other-IDs] NLM/ PMC2680369
  •  go-up   go-down


8. Vitale A, Guarini A, Ariola C, Meloni G, Perbellini O, Pizzuti M, De Gregoris C, Mettivier V, Pastorini A, Pizzolo G, Vignetti M, Mandelli F, Foà R: Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica; 2007 Mar;92(3):342-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial.
  • BACKGROUND AND OBJECTIVES: The prognostic value of myeloid antigen (MyAg) expression in adult acute lymphoblastic leukemia (ALL) is still controversial.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, CD13 / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Antigens, Neoplasm / biosynthesis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Randomized Controlled Trials as Topic / statistics & numerical data
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blood Cell Count. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / mortality. Burkitt Lymphoma / radiotherapy. Cell Lineage. Cohort Studies. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / mortality. Leukemia-Lymphoma, Adult T-Cell / radiotherapy. Male. Middle Aged. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Radiotherapy, Adjuvant. Remission Induction. Sialic Acid Binding Ig-like Lectin 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339183.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Neoplasm; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; 04079A1RDZ / Cytarabine; EC 3.4.11.2 / Antigens, CD13; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


9. Nygren MK, Døsen-Dahl G, Stubberud H, Wälchli S, Munthe E, Rian E: beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells. Exp Hematol; 2009 Feb;37(2):225-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] beta-catenin is involved in N-cadherin-dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1-positive B acute lymphoblastic leukemia cells.
  • OBJECTIVE: The t(1;19)(q23;13) translocation, resulting in the production of the E2A-PBX1 chimeric protein, is a common nonrandom translocation in pediatric B-lineage acute lymphoblastic leukemia (B-ALL).
  • [MeSH-major] Cadherins / metabolism. Homeodomain Proteins / metabolism. Leukemia, B-Cell / metabolism. Oncogene Proteins, Fusion / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Signal Transduction. Wnt Proteins / metabolism. beta Catenin / metabolism


10. Spiegler BJ, Kennedy K, Maze R, Greenberg ML, Weitzman S, Hitzler JK, Nathan PC: Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol; 2006 Aug 20;24(24):3858-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
  • PURPOSE: Cranial radiation therapy (CRT) is associated with neurocognitive morbidity in survivors of childhood acute lymphoblastic leukemia (ALL).
  • RESULTS: Neurocognitive assessment was conducted at least 5 years after diagnosis (mean, 10.5 years, standard deviation, 2.7 years).
  • [MeSH-major] Cognition / drug effects. Cognition / radiation effects. Cranial Irradiation / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):734-5; author reply 735 [17308283.001]
  • [ErratumIn] J Clin Oncol. 2006 Nov 10;24(32):5181
  • (PMID = 16921038.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Goldstein BD: Benzene as a cause of lymphoproliferative disorders. Chem Biol Interact; 2010 Mar 19;184(1-2):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because benzene is a known cause of human acute myelogenous leukemia there has been little reason for organizations such as the International Agency for Research on Cancer (IARC) or the US National Toxicology Program (NTP) to perform standard hazard identification reviews of benzene as a possible cause of other cancers such as lymphomas.
  • Increased understanding of underlying mechanisms of carcinogenesis, as is reflected in the greater scope given to mechanistic evidence in assigning overall sufficiency of evidence for carcinogenicity by both IARC and NTP, suggests that the evidence supporting benzene as a cause of lymphoma likely has passed the threshold required for being listed as a known causal relationship.
  • Furthermore, the classification of lymphomas has evolved so that non-Hodgkin lymphoma now includes such formerly distinct disorders as chronic lymphocytic leukemia and multiple myeloma, and there is less of a distinction between leukemia and non-leukemia forms of lymphoma.
  • [MeSH-minor] Animals. DNA Damage. Humans. Lymphoma / chemically induced. Lymphoma / classification. Lymphoma / epidemiology. Mice

  • Hazardous Substances Data Bank. BENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20035727.001).
  • [ISSN] 1872-7786
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] J64922108F / Benzene
  • [Number-of-references] 54
  •  go-up   go-down


12. Oka S, Nagatsuka Y, Kikuchi J, Yokote T, Hirabayashi Y, Hanafusa T, Ozawa K, Muroi K: Preferential expression of phosphatidylglucoside along neutrophil differentiation pathway. Leuk Lymphoma; 2009 Jul;50(7):1190-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A positive correlation between PtdGlc expression and CD15 expression in leukemic cells from patients with acute myeloblastic leukemia was shown.
  • [MeSH-minor] Antibodies, Monoclonal / chemistry. Antigens, CD15 / biosynthesis. Antigens, CD34 / biosynthesis. Cell Differentiation. Cell Separation. Flow Cytometry / methods. HL-60 Cells. Humans. Leukemia, Myeloid, Acute / metabolism. Phenotype. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19557640.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD15; 0 / Antigens, CD34; 0 / Glycerophospholipids; 0 / phosphatidylglucose
  •  go-up   go-down


13. Eichenauer DA, Fuchs M, Borchmann P, Engert A, German Hodgkin Study Group: Hodgkin's lymphoma: current treatment strategies and novel approaches. Expert Rev Hematol; 2008 Oct;1(1):63-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hodgkin's lymphoma: current treatment strategies and novel approaches.
  • Approximately 80% of Hodgkin's lymphoma (HL) patients achieve long-term remission after primary chemotherapy or chemo/radiotherapy.
  • HL therapy is associated with severe acute and long-term toxicities.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21083007.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  •  go-up   go-down


14. Schlenk RF, Pasquini MC, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A, CIBMTR Acute Leukemia Working Committee: HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant; 2008 Feb;14(2):187-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
  • We studied the role of HLA-matched sibling hematopoietic cell transplantation (HCT) in treating t(8;21) acute myelogenous leukemia (AML) in first remission.
  • In both cohorts, white blood cell count (WBC) at diagnosis >25 x 10(9)/L was associated with a higher relapse risk (RR = 2.09, P = .03), lower relapse-free (RR = 1.9, P = .008), and OS (RR = 1.91, P = .01).

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3767-75 [10577848.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5074-87 [16051954.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):175-81 [11172139.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):300-7 [11167822.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):67-77 [11426630.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1309-10 [11965278.001]
  • [Cites] Blood. 2002 May 15;99(10):3517-23 [11986202.001]
  • [Cites] Blood. 2002 Aug 1;100(3):761-7 [12130483.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):385-400 [12139722.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1525-31 [12176866.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2292-302 [12239137.001]
  • [Cites] Blood. 2003 Jul 15;102(2):462-9 [12649129.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1521-8 [12886238.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4496-504 [14673036.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Ann Hematol. 2004 Jun;83(6):336-44 [15034758.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3741-50 [15289486.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1081-6 [2754449.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1825-31 [1391946.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1288-95 [8709633.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5705-17 [16110030.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):165-73 [16939487.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1687-91 [8892667.001]
  • [Cites] Eur J Haematol. 1997 Jul;59(1):47-52 [9260580.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2978-86 [9376578.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] N Engl J Med. 1998 Dec 3;339(23):1649-56 [9834301.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • (PMID = 18215779.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518-10; United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-09; United States / NCI NIH HHS / CA / U24-CA76518; United States / NCI NIH HHS / CA / U24 CA076518-08; United States / NCI NIH HHS / CA / CA076518-08
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS39951; NLM/ PMC2531160
  •  go-up   go-down


15. Robin M, Porcher R, de Castro R, Fisher G, de Latour RP, Ribaud P, Petropoulou AD, Rocha V, Devergie A, Mary JY, Socié G: Initial liver involvement in acute GVHD is predictive for nonrelapse mortality. Transplantation; 2009 Nov 15;88(9):1131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial liver involvement in acute GVHD is predictive for nonrelapse mortality.
  • BACKGROUND: Current grading systems in acute graft-versus-host disease (GVHD) are not able to identify patients with poor prognosis at time of onset, because they take into account maximal grade.
  • METHODS: The study sample was composed of 142 allogeneic hematopoietic stem-cell transplant recipients who developed acute GVHD after a myeloablative conditioning regimen.
  • RESULTS: At time of diagnosis, GVHD involved a single organ in the majority of the patients (78%).
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Cyclophosphamide / therapeutic use. Erythrocyte Transfusion / statistics & numerical data. Female. Humans. Lymphoma / surgery. Male. Platelet Transfusion / statistics & numerical data. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods. Whole-Body Irradiation. Young Adult

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898210.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


16. Hansson F, Toporski J, Månsson R, Johansson B, Norén-Nyström U, Jacobsen SE, Wiebe T, Larsson M, Sigvardsson M, Castor A: Exit of pediatric pre-B acute lymphoblastic leukaemia cells from the bone marrow to the peripheral blood is not associated with cell maturation or alterations in gene expression. Mol Cancer; 2008;7:67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exit of pediatric pre-B acute lymphoblastic leukaemia cells from the bone marrow to the peripheral blood is not associated with cell maturation or alterations in gene expression.
  • BACKGROUND: Childhood pre-B acute lymphoblastic leukemia (ALL) is a bone marrow (BM) derived disease, which often disseminates out of the BM cavity, where malignant cells to a variable degree can be found circulating in the peripheral blood (PB).
  • [MeSH-major] Blood Cells / metabolism. Bone Marrow Cells / metabolism. Gene Expression. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Genes Dev. 2000 Aug 15;14(16):1983-91 [10950862.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):511-21 [10953026.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19069-74 [16354839.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2247-56 [11187916.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):954-8 [12087404.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Exp Med. 1996 Dec 1;184(6):2217-29 [8976177.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4150-66 [9834220.001]
  • [Cites] Cell. 2005 Apr 22;121(2):295-306 [15851035.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • (PMID = 18694513.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501838
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2525657
  •  go-up   go-down


17. Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA, Chauncey TR, Bruno B, Forman SJ, McSweeney PA, Maziarz RT, Pulsipher MA, Agura ED, Wade J, Sorror M, Maloney DG, Sandmaier BM: Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol; 2006 Sep 1;24(25):4150-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The best outcomes were observed in patients with non-Hodgkin's lymphoma, whereas patients with multiple myeloma and Hodgkin's disease had worse outcomes as a result of high incidences of relapse and progression.
  • Factors associated with better overall survival were PR or CR (P = .01) and lack of comorbidity (P = .03) at HCT and absence of acute GVHD after HCT (P = .06).
  • CONCLUSION: Encouraging outcomes were seen with allogeneic HCT after nonmyeloablative conditioning in selected patients who had experienced relapse after a high-dose HCT, particularly in patients with non-Hodgkin's lymphoma.

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896000.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA18029; United States / NHLBI NIH HHS / HL / HL36444; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / CA92058; United States / NCI NIH HHS / CA / CA49605; United States / NCI NIH HHS / CA / CA15704; United States / NCI NIH HHS / CA / P01 CA078902
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists
  •  go-up   go-down


18. Wang E, Stoecker M: "Cannibalistic" phagocytosis in acute megakaryoblastic leukemia (AML M7) with t(10;17)(p15;q22). Leuk Lymphoma; 2010 Oct;51(10):1944-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Cannibalistic" phagocytosis in acute megakaryoblastic leukemia (AML M7) with t(10;17)(p15;q22).
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / immunology. Phagocytosis / immunology. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20846092.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


19. Pitman SD, Wang J, Serros ER, Zuppan C: A 70-year-old woman with acute renal failure. Crystal-storing histiocytosis. Arch Pathol Lab Med; 2006 Jul;130(7):1077-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 70-year-old woman with acute renal failure. Crystal-storing histiocytosis.
  • Crystal-storing histiocytosis (CSH) is a rare disorder characterized by accumulation of immunoglobulin light chain within histiocytes in one or more organ systems, typically in association with multiple myeloma or, less frequently, with other conditions such as lymphoplasmacytic lymphoma, the use of certain medications, or even polyclonal gammopathies.
  • [MeSH-major] Acute Kidney Injury / pathology. Histiocytes / pathology. Histiocytosis / pathology. Kidney / pathology. Multiple Myeloma / pathology

  • Genetic Alliance. consumer health - Histiocytosis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831042.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains
  •  go-up   go-down


20. Stiller CA, Kroll ME, Boyle PJ, Feng Z: Population mixing, socioeconomic status and incidence of childhood acute lymphoblastic leukaemia in England and Wales: analysis by census ward. Br J Cancer; 2008 Mar 11;98(5):1006-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population mixing, socioeconomic status and incidence of childhood acute lymphoblastic leukaemia in England and Wales: analysis by census ward.
  • In this population-based study of acute lymphoblastic leukaemia (ALL) diagnosed among children aged under 15 years in England and Wales during 1986-1995, we analysed incidence at census ward level in relation to a range of variables from the 1991 census, which could be relevant to theories of infectious aetiology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Aug;12(6):483-90 [11519756.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1411-3 [11986772.001]
  • [Cites] Eur J Cancer. 2002 Oct;38(15):2033-40 [12376209.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):695-8 [12618876.001]
  • [Cites] Am J Epidemiol. 2003 Aug 15;158(4):328-36 [12915498.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):243-63 [15491284.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Lancet. 1990 Sep 8;336(8715):577-82 [1975376.001]
  • [Cites] J Public Health Med. 1990;12(2):109-17 [2223195.001]
  • [Cites] Lancet. 1990 Dec 15;336(8729):1461-5 [1979091.001]
  • [Cites] BMJ. 1991 Nov 30;303(6814):1357-62 [1760600.001]
  • [Cites] BMJ. 1994 Nov 5;309(6963):1197-202 [7987150.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] BMJ. 1995 Mar 25;310(6982):763-8 [7711579.001]
  • [Cites] BMJ. 1996 Nov 23;313(7068):1297-300 [8942689.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):239-45 [9134248.001]
  • [Cites] Br J Cancer. 1997;76(12):1539-45 [9413937.001]
  • [Cites] Int J Epidemiol. 1998 Aug;27(4):587-91 [9758111.001]
  • [Cites] Br J Cancer. 1999 Jan;79(1):30-3 [10408689.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):144-51 [10487626.001]
  • [Cites] Public Health Rep. 1965 Jul;80:573-8 [14310581.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):2084-8 [15886703.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):526-31 [15951671.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):140-4 [17533404.001]
  • [CommentIn] Br J Cancer. 2008 Oct 7;99(7):1194; author reply 1191-3 [18827825.001]
  • (PMID = 18253115.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2266854
  •  go-up   go-down


21. Brown C, Walshe JJ: Disseminated lymphoma presenting as acute thigh pain and renal failure. Ren Fail; 2009;31(3):246-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated lymphoma presenting as acute thigh pain and renal failure.
  • A 66-year-old diabetic man presented with severe right thigh swelling and pain together with acute renal failure.
  • At autopsy, this was found to be due to disseminated high grade B cell lymphoma invading the psoas muscle and multiple organs, including the kidneys.
  • The unique presentation of this case emphasizes the need for increased awareness of the variety of ways in which lymphoma can manifest itself.
  • [MeSH-major] Kidney Neoplasms / complications. Kidney Neoplasms / diagnosis. Lower Extremity. Lymphoma, B-Cell / diagnosis. Muscle Neoplasms / complications. Muscle Neoplasms / diagnosis. Pain / etiology. Renal Insufficiency / etiology
  • [MeSH-minor] Acute Disease. Aged. Diagnosis, Differential. Edema / etiology. Erythema / etiology. Heart Neoplasms / diagnosis. Humans. Male. Psoas Muscles / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288331.001).
  • [ISSN] 1525-6049
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Li S: Src kinases as targets for B cell acute lymphoblastic leukaemia therapy. Expert Opin Ther Targets; 2005 Apr;9(2):329-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Src kinases as targets for B cell acute lymphoblastic leukaemia therapy.
  • The participation of Src kinases in the induction of BCR-ABL-induced B cell acute lymphoblastic leukaemia (B-ALL), but not chronic myeloid leukaemia (CML), demonstrates cell type-specific signalling in Philadelphia chromosome-positive (Ph+) leukaemias.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / enzymology. Drug Delivery Systems / methods. Protein Kinase Inhibitors / therapeutic use. src-Family Kinases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934919.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.2 / src-Family Kinases
  • [Number-of-references] 114
  •  go-up   go-down


23. Wei YF, Wang SY, Ren LL: [Efficacy of shenqi fuzheng injection combined with chemotherapy in treatment of acute leukemia and its effect on T-lymphocyte subsets, serum IFN-gamma, IL-10 and IL-2]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Apr;25(4):303-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of shenqi fuzheng injection combined with chemotherapy in treatment of acute leukemia and its effect on T-lymphocyte subsets, serum IFN-gamma, IL-10 and IL-2].
  • OBJECTIVE: To investigate the clinical efficacy of Shenqi Fuzheng Injection (SFI) combined with chemotherapy in treatment of patients with acute leukemia and its effect on the levels of T-lymphocyte subsets (CD4, CD8, CD4/CD8) and serum interferon-gamma(IFN-gamma), interleukin-10 (IL-10) and IL-2.
  • METHODS: Sixty-five patients with initial treating acute leukemia were randomly divided into 2 groups, the SFI group (n = 32) treated with SFI plus chemotherapy (CT), the control group (n = 33) treated with CT only.
  • CONCLUSION: SFI can improve and regulate the immune function of the patients with acute leukemia undergoing CT, it could promote bone marrow cells proliferation and enhance the efficacy.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15892271.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Drugs, Chinese Herbal; 0 / Interleukin-2; 130068-27-8 / Interleukin-10; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


24. Bernt KM, Armstrong SA: Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol; 2009 Jan;46(1):33-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia stem cells and human acute lymphoblastic leukemia.
  • Leukemia stem cells are fairly well described for acute myeloid leukemia (AML), but their existence and relevance for acute lymphoblastic leukemia (ALL) is less clear.
  • [MeSH-major] Neoplastic Stem Cells / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Hepatology. 2006 Jul;44(1):240-51 [16799977.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4 [17097610.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Science. 2007 Apr 27;316(5824):600-4 [17463288.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63 [17548814.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2542-56 [17570225.001]
  • [Cites] Curr Drug Targets. 2007 Jun;8(6):703-14 [17584026.001]
  • [Cites] Science. 2007 Jul 20;317(5836):337 [17641192.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2240-5 [17657218.001]
  • [Cites] Science. 2007 Dec 14;318(5857):1722; author reply 1722 [18079385.001]
  • [Cites] Cell Mol Immunol. 2007 Dec;4(6):467-72 [18163959.001]
  • [Cites] Science. 2008 Jan 18;319(5861):336-9 [18202291.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):638-48 [17932721.001]
  • [Cites] Br J Cancer. 2008 Feb 26;98(4):756-65 [18268494.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Feb;21(1):39-55 [18353142.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jun;47(6):471-80 [18311775.001]
  • [Cites] Cancer Cell. 2008 Jun;13(6):483-95 [18538732.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):47-58 [18598943.001]
  • [Cites] Blood. 2008 Aug 1;112(3):568-75 [18523148.001]
  • [Cites] Blood. 2000 Feb 1;95(3):1007-13 [10648416.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3925-30 [11389036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8242-7 [12048236.001]
  • [Cites] Blood. 2002 Jul 15;100(2):640-6 [12091359.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):173-83 [12620411.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Blood. 2004 May 1;103(9):3544-6 [14670924.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33 [15381773.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2919-25 [15242869.001]
  • [Cites] Br J Cancer. 1973 Aug;28(2):123-35 [4730176.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Leukemia. 1996 May;10(5):795-802 [8656674.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Leukemia. 1997 Sep;11(9):1508-15 [9305606.001]
  • [Cites] Leukemia. 1998 May;12(5):666-74 [9593263.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1442-9 [15735032.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9339-44 [16990346.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):257-68 [17045204.001]
  • (PMID = 19100366.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA068484; United States / NCI NIH HHS / CA / T32 CA009172
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  • [Other-IDs] NLM/ NIHMS89422; NLM/ PMC4031465
  •  go-up   go-down


25. Luczynski W, Kowalczuk O, Stasiak-Barmuta A, Ilendo E, Krawczuk-Rybak M, Chyczewski L: Acute lymphoblastic leukemia-derived dendritic cells express tumor associated antigens: PNPT1, PMPCB, RHAMM, BSG and ERCC1. Neoplasma; 2009;56(5):428-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia-derived dendritic cells express tumor associated antigens: PNPT1, PMPCB, RHAMM, BSG and ERCC1.
  • Acute lymphoblastic leukemia (ALL) cells are ineffective antigen presenting cells, but as shown by many authors including results from our laboratory, stimulation with CD40L restores their antigen expressing capacity.
  • [MeSH-major] Antigens, CD147 / genetics. Antigens, CD44 / genetics. Antigens, Neoplasm / genetics. DNA-Binding Proteins / genetics. Dendritic Cells / metabolism. Endonucleases / genetics. Exoribonucleases / genetics. Extracellular Matrix Proteins / genetics. Metalloendopeptidases / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19580345.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / BSG protein, human; 0 / DNA-Binding Proteins; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger; 0 / hyaluronan-mediated motility receptor; 136894-56-9 / Antigens, CD147; 147205-72-9 / CD40 Ligand; 207137-56-2 / Interleukin-4; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.13.- / PNPT1 protein, human; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.64 / mitochondrial processing peptidase
  •  go-up   go-down


26. Krenauer A, Moll A, Pönisch W, Schmitz N, Niedobitek G, Niederwieser D, Aigner T: EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression--a case report. Diagn Pathol; 2010;5:21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression--a case report.
  • In support of this notion, reduction of immunosuppressive therapy may lead to regression of PTLD.We present a case of an 18-year-old male developing a monomorphic B-cell PTLD 2 months after receiving an allogenic stem cell transplant for acute lymphoblastic leukemia.
  • [MeSH-major] B-Lymphocytes / virology. Epstein-Barr Virus Infections / etiology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lymph Nodes / virology. Lymphoproliferative Disorders / virology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Immunol. 1984 Sep;87(2):646-58 [6088089.001]
  • [Cites] Lancet. 1984 Mar 17;1(8377):583-7 [6142304.001]
  • [Cites] J Immunol. 1996 Oct 1;157(7):3054-64 [8816415.001]
  • [Cites] Semin Diagn Pathol. 1997 Feb;14(1):8-14 [9044505.001]
  • [Cites] Cancer Surv. 1997;30:143-62 [9547991.001]
  • [Cites] Springer Semin Immunopathol. 1998;20(3-4):389-403 [9870253.001]
  • [Cites] Transplantation. 1998 Dec 27;66(12):1770-9 [9884275.001]
  • [Cites] Lancet. 1964 Mar 28;1(7335):702-3 [14107961.001]
  • [Cites] Annu Rev Med. 2005;56:29-44 [15660500.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1661-7 [16149091.001]
  • [Cites] Annu Rev Immunol. 2007;25:587-617 [17378764.001]
  • [Cites] Bone Marrow Transplant. 2008 Aug;42(3):181-6 [18516079.001]
  • [Cites] Transpl Infect Dis. 1999 Sep;1(3):204-12 [11428990.001]
  • [Cites] Transpl Infect Dis. 2001 Sep;3(3):177-85 [11493400.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):145-55 [12621474.001]
  • [Cites] Tissue Antigens. 2004 Apr;63(4):285-92 [15009802.001]
  • [Cites] Best Pract Res Clin Haematol. 2004 Sep;17(3):401-13 [15498712.001]
  • [Cites] Transplantation. 1988 Apr;45(4):719-27 [2833828.001]
  • (PMID = 20356360.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ PMC2853499
  • [General-notes] NLM/ Original DateCompleted: 20100609
  •  go-up   go-down


27. Naithani R, Kumar R, Saxena R, Mahapatra M: Transformation of myelodysplastic syndrome to T-cell acute lymphoblastic leukemia in a young adult. Pediatr Hematol Oncol; 2009 Mar;26(2):100-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of myelodysplastic syndrome to T-cell acute lymphoblastic leukemia in a young adult.
  • [MeSH-major] Cell Transformation, Neoplastic. Myelodysplastic Syndromes / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / etiology


28. Agarwal MR, Wagner P, Bedros AA: Unilateral optic nerve edema as the initial sign of recurrence of acute lymphoblastic leukemia. J Pediatr; 2006 May;148(5):703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral optic nerve edema as the initial sign of recurrence of acute lymphoblastic leukemia.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / complications. Papilledema / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737892.001).
  • [ISSN] 0022-3476
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Panzer-Grümayer ER, Cazzaniga G, van der Velden VH, del Giudice L, Peham M, Mann G, Eckert C, Schrauder A, Germano G, Harbott J, Basso G, Biondi A, van Dongen JJ, Gadner H, Haas OA: Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection. Clin Cancer Res; 2005 Nov 1;11(21):7720-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection.
  • PURPOSE: Variations of the immunogenotype and TEL deletions in children with TEL-AML1+ acute lymphoblastic leukemia support the hypothesis that relapses derive from a persistent TEL-AML1+ preleukemic/leukemic clone rather than a resistant leukemia.
  • We aimed at elucidating the relationship between the immunogenotype patterns at diagnosis and relapse as well as their clinical and biological relevance.
  • PATIENTS AND METHODS: Immunoglobulin and T-cell receptor gene rearrangements were analyzed in 41 children with a TEL-AML1+ acute lymphoblastic leukemia and an early (up to 30 months after diagnosis; n = 12) or late (at 30 months or later; n = 29) disease recurrence by a standardized PCR approach.
  • The frequency and number of clonal immunoglobulin/T-cell receptor rearrangements in group I was higher at diagnosis (2-13, median 5) than at relapse (2-7, median 4), whereas it was the lowest in group II (1-5, median 3).
  • Although group I children were younger at diagnosis, there was no correlation between particular immunogenotype patterns and remission duration.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / biosynthesis. Core Binding Factor Alpha 2 Subunit / genetics. Gene Rearrangement. Genetic Techniques. Genotype. Oncogene Proteins, Fusion / biosynthesis. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278392.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Core Binding Factor Alpha 2 Subunit; 0 / Immunoglobulins; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Antigen, T-Cell; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


30. Rifkind J, Mollee P, Messner HA, Lipton JH: Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look? Leuk Lymphoma; 2005 Feb;46(2):217-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?
  • Mantle cell lymphoma is a subtype of non-Hodgkin's lymphoma.
  • Allogeneic transplantation is associated with substantial mortality post-transplant from acute toxicity and GVHD.
  • Survival from the date of diagnosis is a median of 6.5 plus years.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Mantle-Cell / therapy

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621804.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Niwa A, Matsubara H, Adachi S, Fujino H, Higashi Y, Umeda K, Shiota M, Hiramatsu H, Kobayashi M, Watanabe K, Yorifuji T, Nakahata T: Diabetes mellitus after stem cell transplantation in a patient with acute lymphoblastic leukemia: possible association with tacrolimus. Pediatr Int; 2007 Aug;49(4):530-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diabetes mellitus after stem cell transplantation in a patient with acute lymphoblastic leukemia: possible association with tacrolimus.
  • [MeSH-major] Diabetes Mellitus, Type 2 / chemically induced. Immunosuppressive Agents / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Stem Cell Transplantation. Tacrolimus / adverse effects


32. Panagopoulos I, Kerndrup G, Carlsen N, Strömbeck B, Isaksson M, Johansson B: Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12). Br J Haematol; 2007 Jan;136(2):294-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12).
  • Three NUP98 chimaeras have previously been reported in T cell acute lymphoblastic leukaemia (T-ALL): NUP98/ADD3, NUP98/CCDC28A, and NUP98/RAP1GDS1.
  • SETBP1 has previously not been implicated in leukaemias; however, it encodes a protein that specifically interacts with SET, fused to NUP214 in a case of acute undifferentiated leukaemia.
  • [MeSH-major] Carrier Proteins / genetics. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 18. Leukemia-Lymphoma, Adult T-Cell / genetics. Nuclear Pore Complex Proteins / genetics. Nuclear Proteins / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17233820.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Nuclear Pore Complex Proteins; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / SETBP1 protein, human; 0 / nuclear pore complex protein 98
  •  go-up   go-down


33. Kourti M, Vavatsi N, Gombakis N, Tzimagiorgis G, Sidi V, Koliouskas D, Athanassiadou F: Increased expression of multidrug resistance gene (MDR1) at relapse in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2006 Sep;23(6):489-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of multidrug resistance gene (MDR1) at relapse in a child with acute lymphoblastic leukemia.
  • Modern treatment protocols lead to complete remission in a high proportion of patients with childhood acute lymphoblastic leukemia (ALL).
  • In order to contribute further information we present a rare case of a 15-month old girl with newly diagnosed CALLA positive pre-B acute lymphoblastic leukemia with favourable prognostic factors at diagnosis who experienced a relapse of the disease.
  • Using reverse transcriptase polymerase chain reaction method, m-RNA expression of the MDR1 gene upon relapse, was five-fold compared with that at diagnosis.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. P-Glycoprotein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Female. Humans. Infant. Neprilysin. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Messenger / analysis. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849280.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / RNA, Messenger; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


34. Perales MA, Jenq R, Goldberg JD, Wilton AS, Lee SS, Castro-Malaspina HR, Hsu K, Papadopoulos EB, van den Brink MR, Boulad F, Kernan NA, Small TN, Wolden S, Collins NH, Chiu M, Heller G, O'Reilly RJ, Kewalramani T, Young JW, Jakubowski AA: Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transplant; 2010 Sep;45(9):1408-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT.
  • We investigated this approach in 61 patients with primary refractory or relapsed non-Hodgkin lymphoma (NHL), who underwent TCD-HSCT from January 1992 through September 2004.
  • The incidence of grades II-IV acute GVHD was 18%.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Nov 1;100(9):3108-14 [12384406.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Bone Marrow Transplant. 2003 Jan;31(2):73-8 [12621486.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] Ann Oncol. 2003 May;14(5):737-44 [12702528.001]
  • [Cites] Blood. 2003 Sep 15;102(6):1989-96 [12676776.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3521-9 [12893748.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4407-12 [14645431.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] Blood. 1994 Aug 15;84(4):1050-5 [8049425.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):855-64 [9217189.001]
  • [Cites] Blood. 1998 Feb 1;91(3):1083-90 [9446672.001]
  • [Cites] Bone Marrow Transplant. 1998 May;21(9):893-9 [9613781.001]
  • [Cites] Bone Marrow Transplant. 1998 Jun;21(12):1177-81 [9674848.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1832-6 [9716615.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):154-61 [10520036.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3535-42 [15304387.001]
  • [Cites] Blood. 2006 Jul 1;108(1):382-9 [16522821.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4552-9 [17717135.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 May;15(5):554-63 [19361747.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2399-404 [11001890.001]
  • [Cites] Bone Marrow Transplant. 2000 Oct;26(8):859-64 [11081385.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2419-23 [15197204.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Transplantation. 1985 Sep;40(3):317-22 [3875918.001]
  • [Cites] N Engl J Med. 1987 Jun 11;316(24):1493-8 [3295541.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2227-36 [2804361.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1630-6 [2809679.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3595-9 [11739162.001]
  • (PMID = 20062091.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA023766; United States / NIAID NIH HHS / AI / R01 AI080455; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / P01 CA023766-32; United States / NCI NIH HHS / CA / P01 CA23766; United States / NCI NIH HHS / CA / CA023766-32
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS282671; NLM/ PMC3076892
  •  go-up   go-down


35. Ragage F, Parrens M, Banos A, Renoux M, Bégueret H, Merlio JP, de Mascarel A: [Lymphomatoid granulomatosis after treatment of an acute myeloid leukemia]. Ann Pathol; 2006 Feb;26(1):22-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphomatoid granulomatosis after treatment of an acute myeloid leukemia].
  • We report a case of lymphomatoid granulomatosis (LG), arising in a 60-year-old man in the setting of an acute myeloid leukemia.
  • The differential diagnosis mainly includes pulmonary vasculitis and Hodgkin's lymphoma.
  • The outcome of this lymphoproliferation is highly variable, ranging from an indolent process to an aggressive large cell lymphoma.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Lymphomatoid Granulomatosis / pathology
  • [MeSH-minor] Antigens, CD / analysis. Biopsy. Diagnosis, Differential. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Nuclear Antigens / analysis. Humans. Male. Middle Aged. Tomography, X-Ray Computed


36. Ono K, Iyama S, Matsunaga T, Sato T, Sato Y, Okuda T, Takada K, Kawano Y, Hayashi T, Miyanishi K, Sagawa T, Kobune M, Takimoto R, Kato J, Niitsu Y: [Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma]. Gan To Kagaku Ryoho; 2007 Sep;34(9):1509-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma].
  • A 59-year-old woman received eight cycles of R-CHOP for diffuse large B-cell lymphoma from July, 2004.
  • Clinically, she was experiencing acute hepatitis due to HBV reactivation.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Antibodies, Monoclonal / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatitis B / virology. Hepatitis B virus / physiology. Lamivudine / therapeutic use. Lymphoma, B-Cell / drug therapy. Virus Activation / drug effects

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17876158.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / DNA, Viral; 2T8Q726O95 / Lamivudine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 77238-31-4 / Interferon-beta; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


37. Rényi I, Bárdi E, Udvardi E, Kovács G, Bartyik K, Kajtár P, Masát P, Nagy K, Galántai I, Kiss C: Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. Pathol Oncol Res; 2007;13(1):57-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
  • To prevent acute renal failure in children at risk for developing tumor lysis syndrome due to acute lymphoblastic leukemia or non-Hodgkin's lymphoma treated according to international BFM protocols, we investigated recombinant urate oxidase (rasburicase) in the first Central European openlabeled, prospective, multicenter phase IV trial.
  • Comparing the data of a subgroup of 12 patients receiving rasburicase with that of a historic cohort of 14 patients treated with allopurinol indicated the superiority of rasburicase over allopurinol in prophylaxis and treatment of hyperuricemia in children with leukemia and lymphoma.
  • [MeSH-major] Hyperuricemia / drug therapy. Hyperuricemia / prevention & control. Leukemia / complications. Lymphoma, Non-Hodgkin / complications. Urate Oxidase / therapeutic use

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. Allopurinol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):697-704 [11157020.001]
  • [Cites] Contrib Nephrol. 2005;147:80-92 [15604608.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1048-54 [12942574.001]
  • [Cites] Leukemia. 1997 Nov;11(11):1813-6 [9369411.001]
  • [Cites] Blood. 2001 May 15;97(10):2998-3003 [11342423.001]
  • [Cites] Am J Med. 1980 Apr;68(4):486-91 [7369230.001]
  • [Cites] Support Care Cancer. 2003 Apr;11(4):249-57 [12673464.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] J Pediatr. 1982 Jan;100(1):152-5 [6948943.001]
  • [Cites] Leuk Res. 2005 Apr;29(4):463-5 [15725482.001]
  • (PMID = 17387390.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinant Proteins; 268B43MJ25 / Uric Acid; 63CZ7GJN5I / Allopurinol; EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase
  •  go-up   go-down


38. Rezvani K, Yong AS, Savani BN, Mielke S, Keyvanfar K, Gostick E, Price DA, Douek DC, Barrett AJ: Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood; 2007 Sep 15;110(6):1924-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.
  • To determine whether the leukemia-associated Wilms tumor antigen (WT1) contributes to a graft-versus-leukemia (GVL) effect after allogeneic stem-cell transplantation (SCT) for acute lymphoblastic leukemia (ALL), we studied CD8(+) T-cell responses to WT1 in 10 human lymphocyte antigen (HLA)-A*0201-positive ALL patients during the early phase of immune recovery after SCT (days 30-120).
  • [MeSH-major] Burkitt Lymphoma / therapy. Graft vs Leukemia Effect. Immunologic Memory. Stem Cell Transplantation. T-Lymphocytes / metabolism. WT1 Proteins / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2005 May 15;174(10):6088-94 [15879103.001]
  • [Cites] Immunity. 1999 Aug;11(2):183-90 [10485653.001]
  • [Cites] J Immunol. 2000 Mar 1;164(5):2807-14 [10679124.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2198-203 [10733485.001]
  • [Cites] J Clin Immunol. 2000 May;20(3):195-202 [10941827.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1480-9 [10942395.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2458-64 [10946271.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(5):511-6 [11019840.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3126-32 [11049993.001]
  • [Cites] J Exp Med. 2000 Aug 21;192(4):549-56 [10952724.001]
  • [Cites] Leukemia. 2001 Feb;15(2):293-302 [11236950.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3 Suppl):761s-765s [11300470.001]
  • [Cites] Methods Mol Med. 2002;68:223-37 [11901505.001]
  • [Cites] Cytotherapy. 2002;4(1):29-40 [11953039.001]
  • [Cites] J Immunol. 2002 Jun 1;168(11):5455-64 [12023339.001]
  • [Cites] Blood. 2002 Sep 15;100(6):2132-7 [12200377.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1698-704 [12406915.001]
  • [Cites] J Clin Invest. 2005 Jun;115(6):1616-26 [15931392.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):8210-8 [15944330.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1238-43 [16227988.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Dec;11(12):1014-21 [16338624.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8799-807 [16361568.001]
  • [Cites] Br J Haematol. 2006 Jan;132(1):56-65 [16371020.001]
  • [Cites] Blood. 2006 Jan 1;107(1):205-12 [16144796.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] Clin Immunol. 2006 Aug;120(2):121-8 [16766227.001]
  • [Cites] Cytotherapy. 2007;9(3):245-51 [17464756.001]
  • [Cites] Acta Haematol. 1999;102(2):72-6 [10529509.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Blood. 2000 Jan 1;95(1):286-93 [10607714.001]
  • [Cites] J Immunol. 2000 Feb 15;164(4):1873-80 [10657636.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2711-20 [12433688.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7 [12601144.001]
  • [Cites] Immunogenetics. 2000 Feb;51(2):99-107 [10663572.001]
  • [Cites] Bone Marrow Transplant. 2003 May;31(9):783-8 [12732885.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1988-95 [12743153.001]
  • [Cites] Int J Hematol. 2003 Jul;78(1):56-61 [12894852.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2892-900 [12829610.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2474-86 [14562124.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2318-57 [14562125.001]
  • [Cites] Leukemia. 2004 Jan;18(1):165-6 [14603333.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Feb;10(2):91-105 [14750075.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Jan;10(1):49-57 [14752779.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74 [14762166.001]
  • [Cites] Bone Marrow Transplant. 2004 Apr;33(8):839-46 [14767500.001]
  • [Cites] Br J Haematol. 2004 Jun;125(5):590-600 [15147374.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):481-8 [15160909.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13885-90 [15365188.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2794-800 [15226184.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Leukemia. 1995 Jun;9(6):1060-7 [7596170.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2195-204 [8630379.001]
  • [Cites] Blood. 2005 Jan 15;105(2):865-73 [15280205.001]
  • [Cites] Leukemia. 2005 Feb;19(2):268-74 [15538407.001]
  • [Cites] Cancer Res. 1996 Aug 15;56(16):3771-81 [8706023.001]
  • [Cites] Science. 1996 Oct 4;274(5284):94-6 [8810254.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):560-5 [8992968.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):433-44 [9053463.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1751-67 [9292508.001]
  • [Cites] J Exp Med. 1997 Nov 3;186(9):1407-18 [9348298.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2197-207 [9490709.001]
  • [Cites] Nat Med. 1999 Jul;5(7):839-42 [10395333.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):6571-6 [15905493.001]
  • (PMID = 17505014.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501963
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-A*02:01 antigen; 0 / HLA-A2 Antigen; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / WT1 Proteins
  • [Other-IDs] NLM/ PMC1976363
  •  go-up   go-down


39. Park MJ, Park YH, Ahn HJ, Choi W, Paik KH, Kim JM, Chang YH, Ryoo BY, Yang SH: Secondary hematological malignancies after breast cancer chemotherapy. Leuk Lymphoma; 2005 Aug;46(8):1183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to several reports, the 10 year incidence of secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) after systemic chemotherapy is approximately 1.5%.
  • We encountered diffuse large B-cell lymphoma, angioimmunoblastic lymphoma and mantle cell lymphoma as secondary hematological malignancies after systemic chemotherapy for breast cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Chemotherapy, Adjuvant / adverse effects. Hematologic Neoplasms / chemically induced. Lymphoma / chemically induced. Neoplasms, Second Primary / chemically induced


40. Ficek K, Blamek S, Syguła D, Miszczyk L, Sońta-Jakimczyk D, Tarnawski R: Evaluation of the late effects of CNS prophylactic treatment in childhood acute lymphoblastic leukemia (ALL) using magnetic resonance spectroscopy. Acta Neurochir Suppl; 2010;106:195-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the late effects of CNS prophylactic treatment in childhood acute lymphoblastic leukemia (ALL) using magnetic resonance spectroscopy.
  • PURPOSE: The aim of the study was to evaluate the late changes seen in Magnetic Resonance Spectroscopy (MRS) of the brain in Acute Lymphoblastic Leukemia (ALL) survivors to assess neurotoxicity following prophylactic treatment with cranial irradiation (CRT) and/or intrathecal (ITMTX) and systemic MTX.
  • [MeSH-major] Brain Injuries. Cranial Irradiation / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


41. Agirre X, Román-Gómez J, Jiménez-Velasco A, Garate L, Montiel-Duarte C, Navarro G, Vázquez I, Zalacain M, Calasanz MJ, Heiniger A, Torres A, Minna JD, Prósper F: ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene; 2006 Mar 23;25(13):1862-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia.
  • We have analyzed the regulation and expression of ASPP members, genes implicated in the regulation of the apoptotic function of the TP53 tumor-suppressor gene, in acute lymphoblastic leukemia (ALL).
  • The analyses of 180 patients with ALL at diagnosis showed that the ASPP1 promoter was hypermethylated in 25% of cases with decreased mRNA expression.
  • [MeSH-major] Carrier Proteins / biosynthesis. Carrier Proteins / genetics. DNA Methylation. Gene Expression Regulation, Neoplastic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncogene. 2013 Feb 7;32(6):803
  • (PMID = 16314841.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / Carrier Proteins; 0 / PPP1R13B protein, human
  •  go-up   go-down


42. Bacher U, Schnittger S, Kern W, Hiddemann W, Haferlach T, Schoch C: The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia. Haematologica; 2005 Apr;90(4):558-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
  • We compared the incidence of submicroscopic deletions accompanying balanced translocations using interphase fluorescence in situ hybridization (FISH) in 245 patients with chronic myeloid leukemia (CML), 79 patients with acute lymphoblastic leukemia (ALL) and BCR-ABL (n=70) or MLL rearrangements (n=29), and 412 patients with acute myeloid leukemia (AML) with CBFB-MYH11 (n=122), PML-RARalpha (n=108), AML1-ETO (n=112), or MLL rearrangements (n=98).
  • [MeSH-major] Chromosome Deletion. Fusion Proteins, bcr-abl / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Humans. Reproducibility of Results. Translocation, Genetic


43. Tang Y, Xu X, Song H, Yang S, Shi S, Wei J: Long-term outcome of childhood acute lymphoblastic leukemia treated in China. Pediatr Blood Cancer; 2008 Sep;51(3):380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of childhood acute lymphoblastic leukemia treated in China.
  • RESULTS: Among the 346 newly diagnosed patients, 167 (48.3%) stopped treatment either at diagnosis or during therapy.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Treatment Failure. Treatment Refusal

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18506765.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Milne E, Laurvick CL, Blair E, Bower C, de Klerk N: No sex difference observed in the association between intra-uterine growth and risk of childhood acute lymphoblastic leukaemia. Cancer Causes Control; 2007 Dec;18(10):1227-8; author reply 1229
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No sex difference observed in the association between intra-uterine growth and risk of childhood acute lymphoblastic leukaemia.
  • [MeSH-major] Abortion, Habitual / epidemiology. Birth Weight. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Birth Weight.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Causes Control. 2007 Mar;18(2):219-28 [17206531.001]
  • (PMID = 17828442.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Netherlands
  •  go-up   go-down


45. Battisti V, Schetinger MR, Maders LD, Santos KF, Bagatini MD, Correa MC, Spanevello RM, do Carmo Araújo M, Morsch VM: Changes in acetylcholinesterase (AchE) activity in lymphocytes and whole blood in acute lymphoblastic leukemia patients. Clin Chim Acta; 2009 Apr;402(1-2):114-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in acetylcholinesterase (AchE) activity in lymphocytes and whole blood in acute lymphoblastic leukemia patients.
  • BACKGROUND: Acute lymphoblastic leukemia (ALL) is a type of cancer that affects lymphocytes and it is the most common form of cancer in children.
  • [MeSH-major] Acetylcholinesterase / blood. Lymphocytes / enzymology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185568.001).
  • [ISSN] 1873-3492
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; EC 3.1.1.7 / Acetylcholinesterase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


46. Geenen MM, Bakker PJ, Kremer LC, Kastelein JJ, van Leeuwen FE: Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy. Pediatr Blood Cancer; 2010 Oct;55(4):690-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy.
  • We determined the prevalence of CRFs in long-term survivors of acute lymphoblastic leukemia (ALL) and Wilms tumor.
  • [MeSH-major] Cardiovascular Diseases / etiology. Kidney Neoplasms / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Wilms Tumor / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • (PMID = 20589650.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


47. Sandlund JT, Pui CH, Zhou Y, Behm FG, Onciu M, Razzouk BI, Hijiya N, Campana D, Hudson MM, Ribeiro RC: Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia; 2009 Jun;23(6):1127-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study.
  • There has been a steady improvement in cure rates for children with advanced-stage lymphoblastic non-Hodgkin's lymphoma.
  • To further improve cure rates whereas minimizing long-term toxicity, we designed a protocol (NHL13) based on a regimen for childhood T-cell acute lymphoblastic leukemia, which features intensive intrathecal chemotherapy for central -nervous system-directed therapy and excludes prophylactic cranial irradiation.
  • From 1992 to 2002, 41 patients with advanced-stage lymphoblastic lymphoma were enrolled on the protocol.
  • Adverse events included two induction failures, one death from typhlitis during remission, three relapses and one secondary acute myeloid leukemia.
  • The treatment described here produces high cure rates in children with lymphoblastic lymphoma without the use of prophylactic cranial irradiation.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1340-6 [12663724.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):161-80; discussion 200-2 [12196214.001]
  • [Cites] Blood. 2002 Jul 1;100(1):52-8 [12070008.001]
  • [Cites] Blood. 2002 Jul 1;100(1):43-7 [12070006.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3616-22 [14512392.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Lancet. 1998 Feb 21;351(9102):550-4 [9492773.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] N Engl J Med. 1996 May 9;334(19):1238-48 [8606720.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1368-76 [7751881.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Med Pediatr Oncol. 1990;18(4):273-9 [2355886.001]
  • [Cites] Blood. 1985 Nov;66(5):1110-4 [3840395.001]
  • [Cites] J Clin Oncol. 1983 Sep;1(9):537-41 [6689428.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Cancer. 1980 Feb 15;45(4):630-7 [6986967.001]
  • (PMID = 19194463.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / P30 CA021765-31
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  • [Other-IDs] NLM/ NIHMS161582; NLM/ PMC2843413
  •  go-up   go-down


48. Liesveld JL, Bechelli J, Rosell K, Lu C, Bridger G, Phillips G 2nd, Abboud CN: Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res; 2007 Nov;31(11):1553-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells.
  • Acute myelogenous leukaemia (AML) blasts transmigrate in response to SDF-1alpha.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Leukoc Biol. 2004 Jul;76(1):185-94 [15075362.001]
  • [Cites] Blood. 2004 Jul 15;104(2):550-7 [15054042.001]
  • [Cites] Nat Med. 2004 Aug;10(8):858-64 [15235597.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1501-10 [15370200.001]
  • [Cites] Leukemia. 1994 Dec;8(12):2111-7 [7528857.001]
  • [Cites] Leukemia. 1996 Jun;10(6):1041-7 [8667639.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9448-53 [9689100.001]
  • [Cites] Science. 1999 Feb 5;283(5403):845-8 [9933168.001]
  • [Cites] Blood. 1999 May 15;93(10):3379-90 [10233890.001]
  • [Cites] Circulation. 2004 Nov 23;110(21):3300-5 [15533866.001]
  • [Cites] Leuk Res. 2005 Feb;29(2):185-96 [15607368.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3117-26 [15618475.001]
  • [Cites] J Exp Med. 2005 Apr 18;201(8):1307-18 [15837815.001]
  • [Cites] Stem Cells. 2005 Aug;23(7):879-94 [15888687.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1867-74 [15890685.001]
  • [Cites] Hematology. 2005 Dec;10(6):483-94 [16321813.001]
  • [Cites] Blood. 2001 Feb 1;97(3):799-804 [11157500.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2942-9 [15070669.001]
  • [Cites] Stem Cells. 2004;22(2):188-201 [14990858.001]
  • [Cites] Blood Cells Mol Dis. 2004 Jan-Feb;32(1):52-7 [14757413.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Exp Hematol. 2001 Mar;29(3):345-55 [11274763.001]
  • [Cites] J Hematother Stem Cell Res. 2001 Feb;10(1):81-93 [11276362.001]
  • [Cites] Exp Hematol. 2001 Apr;29(4):448-57 [11301185.001]
  • [Cites] Blood. 2001 May 15;97(10):3283-91 [11342460.001]
  • [Cites] Ann N Y Acad Sci. 2001 Jun;938:26-34; discussion 34-5 [11458515.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1289-97 [11520773.001]
  • [Cites] Exp Hematol. 2001 Dec;29(12):1439-47 [11750103.001]
  • [Cites] Leukemia. 2002 Apr;16(4):650-7 [11960346.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1713-24 [12200686.001]
  • [Cites] FEBS Lett. 2002 Sep 11;527(1-3):255-62 [12220670.001]
  • [Cites] Exp Hematol. 2002 Sep;30(9):973-81 [12225788.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2778-86 [12351385.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1992-2003 [12357350.001]
  • [Cites] J Immunol. 2003 Jan 1;170(1):421-9 [12496427.001]
  • [Cites] J Clin Invest. 2003 Jan;111(2):187-96 [12531874.001]
  • [Cites] Glia. 2003 Apr 15;42(2):139-48 [12655598.001]
  • [Cites] Nat Rev Drug Discov. 2003 Jul;2(7):581-7 [12815382.001]
  • [Cites] Leukemia. 2003 Jul;17(7):1294-300 [12835717.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2728-30 [12855591.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3136-46 [12869505.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8 [14595012.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2900-7 [15070661.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1095-102 [15020611.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2981-9 [15070674.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2817-24 [15087398.001]
  • (PMID = 17403536.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112835-02; United States / NCI NIH HHS / CA / R21 CA112835; United States / NCI NIH HHS / CA / R21 CA112835-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Chemokine CXCL12; 0 / Culture Media; 0 / Heterocyclic Compounds; 155148-31-5 / JM 3100
  • [Other-IDs] NLM/ NIHMS34260; NLM/ PMC2133372
  •  go-up   go-down


49. Ruiz-Argüelles GJ, Fernández-Lara D, Estrada-Gómez R, Manzano C, Ruiz-Delgado GJ, Pérez-Romano B, Ruiz-Argüelles A: Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance. Lab Hematol; 2007;13(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
  • Two main techniques are being used for the detection of minimal residual disease (MRD) in acute leukemia (AL): immunophenotypic analysis and polymerase chain reaction (PCR).
  • (1) acute lymphoblastic leukemia (ALL) patients with MRD (n = 36);.
  • (2) acute myeloblastic leukemia (AML) patients with MRD (n = 13);.
  • [MeSH-major] Leukemia, Myeloid, Acute / blood. Neoplasm Recurrence, Local / blood. Neoplasm, Residual / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353179.001).
  • [ISSN] 1080-2924
  • [Journal-full-title] Laboratory hematology : official publication of the International Society for Laboratory Hematology
  • [ISO-abbreviation] Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


50. Fujisawa S, Nakamura S, Naito K, Kobayashi M, Ohnishi K: A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature. Int J Hematol; 2008 Mar;87(2):184-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature.
  • We report a rare case of adult Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) with an e1a3 fusion transcript.
  • [MeSH-major] Genes, abl / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hematol. 2003 Dec;74(4):268-72 [14635208.001]
  • [Cites] Leukemia. 1998 Dec;12(12):1881-5 [9844918.001]
  • [Cites] Leukemia. 1990 Jun;4(6):397-403 [2193202.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1696-702 [7934165.001]
  • [Cites] Br J Haematol. 1993 Dec;85(4):823-5 [7918054.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2291-9 [12613515.001]
  • [Cites] Br J Haematol. 2001 Sep;114(3):635-7 [11552990.001]
  • [Cites] J Exp Med. 1999 Apr 19;189(8):1229-42 [10209040.001]
  • [Cites] Acta Haematol. 2002;108(3):150-3 [12373087.001]
  • [Cites] Transl Res. 2006 Nov;148(5):249-56 [17145570.001]
  • [Cites] Blood. 2000 Jun 15;95(12):4019-20 [10939800.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1092-3 [12130477.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1791 [7934177.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jan 15;116(2):166-9 [10640151.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1109-11 [11167748.001]
  • [Cites] Leukemia. 1999 Sep;13(9):1463-4 [10483000.001]
  • [Cites] Leukemia. 1991 Jun;5(6):457-61 [2056770.001]
  • [Cites] Leukemia. 1998 Feb;12(2):250 [9519792.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Apr 15;174(2):111-5 [17452251.001]
  • [Cites] Blood. 1998 Jan 15;91(2):406-18 [9427693.001]
  • [Cites] Haematologica. 1999 Jun;84(6):573-5 [10366813.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2375-84 [8839828.001]
  • [Cites] Am J Hematol. 2004 Feb;75(2):92-5 [14755375.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1504-8 [8412311.001]
  • (PMID = 18253707.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 25
  •  go-up   go-down


51. Haider FS, Smith R, Khan S: Primary hepatic lymphoma presenting as fulminant hepatic failure with hyperferritinemia: a case report. J Med Case Rep; 2008;2:279
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic lymphoma presenting as fulminant hepatic failure with hyperferritinemia: a case report.
  • INTRODUCTION: Primary hepatic lymphoma is an unusual form of non-Hodgkin's lymphoma that usually presents with constitutional symptoms, hepatomegaly and signs of cholestatic jaundice.
  • Diffuse hepatic infiltration is uncommon and presentation with acute hepatic failure even more rare.
  • The presence of markedly elevated ferritin levels can complicate the evaluation process and suggest alternative diagnoses.We present the case of a middle-aged woman exhibiting pancytopenia, hyperferritinemia and rapidly deteriorating to develop acute hepatic failure.
  • Her initial clinical picture led to a working diagnosis of adult onset Still's disease with probable hemophagocytic syndrome before her worsening liver function necessitated a percutaneous liver biopsy and establishment of the final diagnosis of primary hepatic lymphoma.
  • CONCLUSION: Primary hepatic lymphoma is an uncommon malignancy and its manifestation as progressive hepatitis or acute fulminant hepatic failure can be difficult to diagnose.
  • A liver biopsy early in the course of liver dysfunction may establish the diagnosis without a higher risk of bleeding complications seen once liver failure sets in.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1995 Oct 15;76(8):1336-43 [8620406.001]
  • [Cites] J Rheumatol. 1996 Mar;23(3):495-7 [8832990.001]
  • [Cites] J Rheumatol. 1992 Sep;19(9):1425-7 [1433011.001]
  • [Cites] Arch Pathol Lab Med. 1986 Jun;110(6):553-5 [3010899.001]
  • [Cites] Age Ageing. 2004 Nov;33(6):637-40 [15381504.001]
  • [Cites] Am J Gastroenterol. 2003 Jul;98(7):1641-6 [12873593.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2023-9 [11596015.001]
  • [Cites] J Rheumatol. 2001 Feb;28(2):322-9 [11246670.001]
  • [Cites] Ann Hematol. 2000 Jul;79(7):378-88 [10965786.001]
  • [Cites] Med Klin (Munich). 2007 Oct 15;102(10):846-51 [17928968.001]
  • [Cites] Acta Gastroenterol Belg. 2007 Apr-Jun;70(2):210-3 [17715636.001]
  • [Cites] J Hepatol. 2007 Aug;47(2):284-94 [17561303.001]
  • [Cites] Clin Lymphoma Myeloma. 2006 Jan;6(4):273-80 [16507204.001]
  • [Cites] Transplantation. 2005 Oct 15;80(7):993-6 [16249751.001]
  • [Cites] Hepatology. 1995 Feb;21(2):345-51 [7843704.001]
  • (PMID = 18710584.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2542397
  •  go-up   go-down


52. Reddick WE, Glass JO, Helton KJ, Langston JW, Xiong X, Wu S, Pui CH: Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol; 2005 May;26(5):1263-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate.
  • BACKGROUND AND PURPOSE: An effective treatment for acute lymphoblastic leukemia (ALL), intravenous (IV) methotrexate (MTX) has a notable toxic effect on the CNS, with leukoencephalopathy (LE) being the most common form.
  • Cox proportional regression was used to estimate the effect of covariates (e.g., sex, MTX dose, age at diagnosis) on the prevalence of LE.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IEEE Trans Med Imaging. 1997 Dec;16(6):911-8 [9533591.001]
  • [Cites] J Pediatr. 1977 Dec;91(6):909-13 [925819.001]
  • [Cites] Med Pediatr Oncol. 1997 Jun;28(6):387-400 [9143382.001]
  • [Cites] J Magn Reson Imaging. 1997 Mar-Apr;7(2):410-5 [9090600.001]
  • [Cites] Med Pediatr Oncol. 2000 Nov;35(5):456-61 [11070477.001]
  • [Cites] J Pediatr. 2001 Sep;139(3):413-20 [11562622.001]
  • [Cites] Magn Reson Med. 2004 Dec;52(6):1336-41 [15562471.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1712-22 [9586883.001]
  • [Cites] Magn Reson Med. 2002 May;47(5):912-20 [11979570.001]
  • [Cites] Isr Med Assoc J. 2002 Nov;4(11):1050-3 [12489505.001]
  • [Cites] Radiology. 2003 Dec;229(3):659-69 [14576448.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] N Engl J Med. 1978 Apr 13;298(15):815-8 [273143.001]
  • [Cites] J Clin Oncol. 1983 Dec;1(12):793-8 [6199470.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Summer;12(2):174-81 [2116096.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):145-51 [1985164.001]
  • [Cites] Radiology. 1991 Jul;180(1):205-9 [2052695.001]
  • [Cites] Cancer. 1992 Oct 1;70(7):1997-2004 [1525778.001]
  • [Cites] Cancer. 1992 Dec 1;70(11):2728-33 [1423204.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1993 May;15(2):231-8 [8498647.001]
  • [Cites] Pediatr Hematol Oncol. 1993 Jul-Sep;10(3):267-70 [8217544.001]
  • [Cites] Neuroradiology. 1996 Apr;38(3):264-8 [8741199.001]
  • (PMID = 15891195.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090246-05; United States / NCI NIH HHS / CA / R01-CA90246; United States / NCI NIH HHS / CA / R01 CA090246; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA090246-05; United States / NCI NIH HHS / CA / P30-CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 24
  • [Other-IDs] NLM/ NIHMS49114; NLM/ PMC2396789
  •  go-up   go-down


53. Srivastava BI, Srivastava MD: Establishment and characterization of SRIK-NKL: a novel CD8+ natural killer/T cell line derived from a patient with leukemic phase of acute lymphoblastic lymphoma. Leuk Res; 2005 Jul;29(7):771-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of SRIK-NKL: a novel CD8+ natural killer/T cell line derived from a patient with leukemic phase of acute lymphoblastic lymphoma.
  • We report the establishment of a permanent CD8+ NK/T cell line (SRIK-NKL) from a patient with leukemic phase of acute lymphoblastic lymphoma having characteristics of both NK and T cells, and extensively describe its phenotype, including cytotoxic activity, NK cell receptor expression, and other molecules critical for immune function.
  • [MeSH-major] Antigens, CD8 / blood. CD8-Positive T-Lymphocytes / immunology. Killer Cells, Natural / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15927673.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA016056-27
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD8
  •  go-up   go-down


54. Yoshida T, Kanegane H, Otsubo K, Nomura K, Hirokawa S, Tsuneyama K, Egawa H, Miyawaki T: Acute lymphoblastic leukemia after living donor liver transplantation. Pediatr Int; 2005 Oct;47(5):579-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia after living donor liver transplantation.
  • [MeSH-major] Liver Transplantation / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology


55. Rafferty AL, Collett MG, Forsyth SF, Neumann EJ, Suepaul RB: Acute B-cell lymphoblastic leukaemia in a 5-month-old boar. N Z Vet J; 2007 Oct;55(5):244-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute B-cell lymphoblastic leukaemia in a 5-month-old boar.
  • CLINICAL FINDINGS AND DIAGNOSIS: The boar had an elevated heart rate, slow capillary refill time and cyanotic skin over the ears; it was also severely anaemic.
  • DIAGNOSIS: B-cell lymphoblastic leukaemia with secondary infiltration of lymphoid organs, kidneys, testis and preputial skin.
  • CLINICAL RELEVANCE: This is the fi rst known reported case of acute B-cell lymphoblastic leukaemia in swine.
  • [MeSH-major] Burkitt Lymphoma / veterinary. Swine Diseases / diagnosis
  • [MeSH-minor] Animals. Blood Cell Count / veterinary. Diagnosis, Differential. Lethargy / etiology. Lethargy / veterinary. Male. Swine

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928902.001).
  • [ISSN] 0048-0169
  • [Journal-full-title] New Zealand veterinary journal
  • [ISO-abbreviation] N Z Vet J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


56. Beer P, Abdalla SH, Matutes E, Bain BJ: Teaching cases from the Royal Marsden and St Mary's Hospital case 29: striking generalized lymphadenopathy in 'acute myeloid leukemia'. Leuk Lymphoma; 2005 Jan;46(1):155-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teaching cases from the Royal Marsden and St Mary's Hospital case 29: striking generalized lymphadenopathy in 'acute myeloid leukemia'.
  • [MeSH-major] Hospitals, Teaching. Leukemia, Myeloid, Acute / complications. Lymphatic Diseases / complications

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15621796.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.1.- / Carboxylic Ester Hydrolases; EC 3.1.1.- / chloroacetate esterase
  •  go-up   go-down


57. Cao L, Guo B, Kang R, Yang M, Zhang Z, Wu X: Identification of a 2-cM minimal deletion at 6q16.3-21 in childhood acute lymphoblastic leukemia in China. Pediatr Blood Cancer; 2005 Oct 15;45(5):732-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a 2-cM minimal deletion at 6q16.3-21 in childhood acute lymphoblastic leukemia in China.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 6 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


58. Nakagawa Y, Hasegawa M, Kurata M, Yamamoto K, Abe S, Inoue M, Takemura T, Hirokawa K, Suzuki K, Kitagawa M: Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL). Am J Hematol; 2005 Mar;78(3):173-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of IAP-family proteins in adult acute mixed lineage leukemia (AMLL).
  • To determine the apoptosis-resistant mechanism in adult acute mixed lineage leukemia (AMLL) with biphenotypic blasts responsible for resistance against chemotherapy, the expression levels of IAP-family proteins in AMLL bone marrow cells were analyzed by quantitative RT-PCR.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / metabolism. Bone Marrow Cells / metabolism. Leukemia, Biphenotypic, Acute / metabolism. Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Flow Cytometry. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Inhibitor of Apoptosis Proteins. Leukemia, Monocytic, Acute / drug therapy. Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology. Male. Microtubule-Associated Proteins / analysis. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Proteins. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15726601.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proteins; 0 / RNA, Messenger
  •  go-up   go-down


59. Busuttil DP: Alopecia areata universalis and acute lymphoblastic leukemia. Am J Hematol; 2007 Sep;82(9):860
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alopecia areata universalis and acute lymphoblastic leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Alopecia Areata / diagnosis. Fatal Outcome. Hematopoietic Stem Cell Transplantation. Humans. Male


60. Miron I, Mihăilă D, Aprodu G, Miron L, Plămădeală P, Moisă SM: Immunoproliferative small intestinal disease versus colonic monoblastic sarcoma in a 2-year-old boy. Rom J Morphol Embryol; 2009;50(4):733-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Important similitudes with immunoproliferative small intestinal disease (IPSID) lymphoma were demonstrated for this patient (male, 2-year-old).
  • Some particularities of this case are the young age and the extremely rapid development of the malignant disease in a patient with no previous signs of acute non-lymphoblastic leukemia.
  • The initial diagnosis was of malabsorbtion syndrome, based on the clinical exam at presentation, and then the patient was thought to have a form of Hirschprung's disease, due to a functional intestinal disorder (slow transit).
  • [MeSH-major] Colonic Neoplasms / diagnosis. Immunoproliferative Small Intestinal Disease / diagnosis. Sarcoma / diagnosis
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Hirschsprung Disease / diagnosis. Humans. Malabsorption Syndromes / diagnosis. Male

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19942975.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


61. Cheson BD, Dutcher BS: Managing malignancy-associated hyperuricemia with rasburicase. J Support Oncol; 2005 Mar-Apr;3(2):117-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The drug initially was studied in pediatric patients with acute lymphoblastic leukemia and aggressive non-Hodgkin lymphoma; data may suggest comparable benefit in adults with similar lymphoid malignancies.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Allopurinol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Support Oncol. 2005 Mar-Apr;3(2):127-8 [15796444.001]
  • (PMID = 15796443.001).
  • [ISSN] 1544-6794
  • [Journal-full-title] The journal of supportive oncology
  • [ISO-abbreviation] J Support Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Free Radical Scavengers; 63CZ7GJN5I / Allopurinol; EC 1.7.3.3 / Urate Oxidase; EC 1.7.3.3. / rasburicase
  • [Number-of-references] 21
  •  go-up   go-down


62. Kang HK, Park JS, Kim SK, Choi BH, Pham TN, Zhu XW, Cho D, Nam JH, Kim YJ, Rhee JH, Chung IJ, Kim HJ, Lee JJ: Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia. Leuk Lymphoma; 2006 Oct;47(10):2224-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemia.
  • Leukemic DCs were successfully generated in vitro from bone marrow cells of 16 of 21 acute myeloid leukemia (AML) patients, and the cellular VEGF concentrations in the leukemic cells and the neutralization of VEGF with anti-VEGF antibody were determined.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071499.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


63. Takami A, Okumura H, Maeda Y, Kumano Y, Asakura H, Oda M, Omura K, Nakao S: Primary tracheal lymphoma: case report and literature review. Int J Hematol; 2005 Nov;82(4):338-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tracheal lymphoma: case report and literature review.
  • We describe a 20-year-old Japanese woman with anaplastic large cell lymphoma in whom primary tracheal involvement was associated with life-threatening airway obstruction.
  • A total of 28 cases of primary tracheal lymphoma were reviewed.
  • Common clinical features included predominance of localized disease, respiratory symptoms resembling acute asthma, absence of hemoptysis, and rapid progression of tracheal stenosis.
  • Various histological subtypes of primary tracheal lymphoma exist and are likely to determine prognosis.
  • [MeSH-major] Lymphoma / diagnosis. Tracheal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for tracheal lymphoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Thorax. 1988 Jun;43(6):497-8 [3262244.001]
  • [Cites] Chin Med J (Engl). 2005 Apr 20;118(8):702-4 [15899129.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2000 Dec;48(12):817-9 [11197829.001]
  • [Cites] Thorax. 2005 Jan;60(1):82-3 [15618589.001]
  • [Cites] Arch Surg. 1969 Aug;99(2):132-40 [4183360.001]
  • [Cites] Ann Thorac Surg. 1999 May;67(5):1448-50 [10355429.001]
  • [Cites] Mayo Clin Proc. 1993 Jul;68(7):680-4 [8394484.001]
  • [Cites] Eur J Surg Oncol. 1992 Oct;18(5):514-6 [1426304.001]
  • [Cites] Pathol Int. 1999 Dec;49(12):1100-4 [10632932.001]
  • [Cites] Anaesth Intensive Care. 1993 Jun;21(3):366-9 [8342776.001]
  • [Cites] Cancer. 1970 Jun;25(6):1448-56 [4316327.001]
  • [Cites] Ann Oncol. 1998;9 Suppl 5:S31-8 [9926235.001]
  • [Cites] Intern Med. 1999 Mar;38(3):276-8 [10337941.001]
  • [Cites] Thorax. 1989 Jun;44(6):519-20 [2788321.001]
  • [Cites] Can Respir J. 2005 Mar;12 (2):86-8 [15785798.001]
  • [Cites] Am J Surg Pathol. 1992 Jan;16(1):71-5 [1728197.001]
  • [Cites] J Rheumatol. 1987 Jun;14(3):588-94 [3625640.001]
  • [Cites] J Thorac Cardiovasc Surg. 1981 Jun;81(6):835-9 [7230854.001]
  • [Cites] Laryngoscope. 1990 Apr;100(4):337-42 [2319881.001]
  • [Cites] J Thorac Cardiovasc Surg. 1975 Nov;70(5):938-40 [1186279.001]
  • [Cites] Tumori. 1984 Feb 29;70(1):109-11 [6710605.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2332-8 [8635104.001]
  • [Cites] Chest. 1999 Sep;116(3):832-5 [10492297.001]
  • [Cites] Chest. 1993 Apr;103(4):1297-9 [8131496.001]
  • [Cites] Pediatr Pathol. 1989;9(3):329-36 [2664742.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Jul-Aug;20(5):399-402 [12775538.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Intern Med. 1992 May;31(5):655-8 [1504430.001]
  • (PMID = 16298827.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 30
  •  go-up   go-down


64. Saito H, Monoe K, Kanno Y, Takahashi A, Rai T, Irisawa A, Ohira H: Two cases of primary biliary cirrhosis complicated by acute leukemia. Intern Med; 2007;46(9):561-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of primary biliary cirrhosis complicated by acute leukemia.
  • She was diagnosed as having acute lymphoid leukemia (ALL) by bone marrow examination.
  • Seven years later, she was diagnosed as having acute promyelocytic leukemia (APL) by bone marrow examination.
  • To date, there have been no reports of PBC complicated by acute leukemia.
  • [MeSH-major] Leukemia, Promyelocytic, Acute / complications. Liver Cirrhosis, Biliary / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Primary biliary cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473489.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.3.1.12 / Dihydrolipoyllysine-Residue Acetyltransferase
  •  go-up   go-down


65. Meisel R, Toschke AM, Heiligensetzer C, Dilloo D, Laws HJ, von Kries R: Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia. Br J Haematol; 2007 Jun;137(5):457-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk for invasive pneumococcal diseases in children with acute lymphoblastic leukaemia.
  • There are no current data available on the risk of IPD in children with acute lymphoblastic leukaemia (ALL), the most common type of childhood malignancy.
  • [MeSH-major] Pneumococcal Infections / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology. Streptococcus pneumoniae

  • MedlinePlus Health Information. consumer health - Pneumococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488489.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


66. An Q, Xue TY, Xu W, Gao JZ, Wu Y, Xu CP: [Effect of N-tosyl-L-phenylalnylchloromethyl ketone and dexamethasone on expression of nuclear transcription factor-kappaB in childhood acute lymphoblastic leukemia and its significance]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr;15(2):399-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of N-tosyl-L-phenylalnylchloromethyl ketone and dexamethasone on expression of nuclear transcription factor-kappaB in childhood acute lymphoblastic leukemia and its significance].
  • In order to investigate the effect of N-tosyl-L-phenylalnylchloromethyl ketone (TPCK) and dexamethasone (Dex) on expression of nuclear transcription factor-kappaB (NF-kappaB) in childhood acute lymphoblastic leukemia (ALL) and its significance, so as to provide the experimental basis for corresponding clinical treatment of ALL, in which NF-kappaB is taken as a target.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493356.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Protein Synthesis Inhibitors; 402-71-1 / Tosylphenylalanyl Chloromethyl Ketone; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


67. Uozumi K: Treatment of adult T-cell leukemia. J Clin Exp Hematop; 2010;50(1):9-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of the aggressive forms (acute and lymphoma types) of ATL remains inadequate, as most ATL patients receive conventional chemotherapy without stem cell rescue.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / therapy

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505272.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  •  go-up   go-down


68. Flora RS, Brito-Babapulle F, Naresh KN: Aberrant positivity for CD79a in erythroid lineage cells--a finding observed in a subset of re-staging bone marrow trephine biopsies after treatment cell pain. Haematologica; 2007 Jun;92(6):855-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant expression of CD79a has been reported in neoplastic cells in peripheral T cell lymphoma, T-cell acute lymphoblastic leukemia and acute myeloid leukemia (especially those with t(8;21)).
  • In all, we document this finding in five of 18 re-staging bone marrow trephine samples in patients of lymphoma treated with chemotherapy (one index case and 17 additional validation cases).
  • [MeSH-major] Antigens, CD79 / analysis. Erythroid Precursor Cells / pathology. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550863.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD79
  •  go-up   go-down


69. Schmidt-Hieber M, Blau IW, Richter G, Türkmen S, Bommer C, Thiel G, Neitzel H, Stroux A, Uharek L, Thiel E, Blau O: Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation. Cancer Genet Cytogenet; 2010 Apr 15;198(2):135-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation.
  • We analyzed karyotype stability in 22 patients with acute leukemia at relapse or disease progression after allogeneic stem cell transplantation (allo-SCT).
  • We conclude that a karyotype change is common at relapse after allo-SCT in acute leukemia patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [ErratumIn] Cancer Genet Cytogenet. 2010 Jul 1;200(1):73
  • (PMID = 20362228.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Zhu N, Gu L, Findley HW, Chen C, Dong JT, Yang L, Zhou M: KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia. J Biol Chem; 2006 May 26;281(21):14711-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia.
  • Transfection of KLF5 into a KLF5-negative acute lymphoblastic leukemia cell line EU-8 enhanced survivin expression, and conversely, silencing of KLF5 by small interfering RNA in a KLF5-overexpressing acute lymphoblastic leukemia cell line EU-4 down-regulated survivin expression.
  • [MeSH-major] Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Kruppel-Like Transcription Factors / physiology. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595680.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 82323
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / KLF5 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Tumor Suppressor Protein p53; 80168379AG / Doxorubicin
  •  go-up   go-down


71. Teo WY, Loh TF, Tan AM: Avoiding dialysis in tumour lysis syndrome: is urate oxidase effective? - a case report and review of literature. Ann Acad Med Singapore; 2007 Aug;36(8):679-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Hyperuricaemia in tumour lysis syndrome (TLS) can cause acute renal failure (ARF), necessitating dialysis.
  • CASE REPORT: An 8-year-old boy with stage 3 Burkitt's lymphoma, TLS was successfully treated with hyper-hydration, diuretics and rasburicase, without dialysis.
  • [MeSH-minor] Burkitt Lymphoma / complications. Child. Humans. Hyperuricemia / drug therapy. Male. Singapore. Treatment Outcome. Uric Acid / analysis. Uric Acid / blood

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17767339.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Singapore
  • [Chemical-registry-number] 268B43MJ25 / Uric Acid; EC 1.7.3.3 / Urate Oxidase
  • [Number-of-references] 20
  •  go-up   go-down


72. Thomas DA, Sarris AH, Cortes J, Faderl S, O'Brien S, Giles FJ, Garcia-Manero G, Rodriguez MA, Cabanillas F, Kantarjian H: Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer; 2006 Jan 1;106(1):120-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
  • BACKGROUND: Outcomes with salvage therapy for patients with recurrent or refractory acute lymphocytic leukemia (ALL) are poor, with complete response (CR) rates reported to be 20-30% and a median survival ranging from 2-6 months.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Salvage Therapy. Vincristine / therapeutic use

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • [ErratumIn] Cancer. 2006 Apr 1;106(7):1641
  • (PMID = 16331634.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Liposomes; 0 / Sphingomyelins; 5J49Q6B70F / Vincristine
  •  go-up   go-down


73. Cantarovich M, Durrbach A, Hiesse C, Ladouceur M, Benoit G, Charpentier B: 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients. Transplantation; 2008 Dec 27;86(12):1732-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The incidence of acute rejection was lower in group 2 (28% vs. 75%, P<0.0001).
  • The incidence of cancer was 22.2% in group 1 and 11.7% in group 2 (P=0.53) and the incidence of lymphoma did not differ (3% vs. 5%, P=0.77).
  • CONCLUSION: The use of ALG-induction resulted in a lower incidence of acute rejection and improved graft survival during the first year postrenal transplantation.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104413.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunologic Factors; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; MRK240IY2L / Azathioprine; VB0R961HZT / Prednisone
  •  go-up   go-down


74. Yang J, Bogni A, Cheng C, Bleibel WK, Cai X, Fan Y, Yang W, Rocha JC, Pei D, Liu W, Dolan ME, Pui CH, Relling MV: Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia. Clin Pharmacol Ther; 2008 Dec;84(6):691-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etoposide sensitivity does not predict MLL rearrangements or risk of therapy-related acute myeloid leukemia.
  • Therapy-related acute myeloid leukemia (t-AML) caused by MLL rearrangements (rMLL) can arise from topoisomerase II agents.
  • We therefore compared (i) rMLL in children with acute lymphoblastic leukemia (ALL) who developed t-AML and those who did not, (ii) epipodophyllotoxin toxicity in patients with t-AML and in controls, and (iii) rMLL in cells sensitive to etoposide and in those resistant to etoposide.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4550-5 [11389089.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):31-6 [17237264.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1377-81 [12649202.001]
  • [Cites] Blood. 2003 May 15;101(10):3862-7 [12531808.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):268-73 [14582077.001]
  • [Cites] FASEB J. 2004 Jan;18(1):173-5 [14630694.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11809-14 [15282376.001]
  • [Cites] Blood. 1987 Nov;70(5):1412-7 [2822173.001]
  • [Cites] Haematol Blood Transfus. 1989;32:58-64 [2625263.001]
  • [Cites] Blood. 1991 Aug 15;78(4):1147-8 [1651134.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8740-3 [1681541.001]
  • [Cites] N Engl J Med. 1991 Dec 12;325(24):1682-7 [1944468.001]
  • [Cites] Lancet. 1991 Dec 7;338(8780):1468 [1683460.001]
  • [Cites] Med Pediatr Oncol. 1992;20(1):48-52 [1727211.001]
  • [Cites] Nucleic Acids Res. 1992 Jan 25;20(2):307-14 [1741256.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1993 Feb;15(1):99-104 [8447565.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3705-11 [8260707.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1680-4 [7564509.001]
  • [Cites] Leukemia. 1995 Dec;9(12):1990-6 [8609707.001]
  • [Cites] J Natl Cancer Inst. 1996 Apr 3;88(7):407-18 [8618232.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2210-8 [8822941.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1787-9 [8961963.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1840-7 [8961974.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Leukemia. 1998 Mar;12(3):346-52 [9529129.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1897-8 [9586907.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):139-54 [9748545.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3386-91 [9779717.001]
  • [Cites] Leukemia. 2005 Feb;19(2):183-90 [15618964.001]
  • [Cites] Pharmacogenomics. 2005 Jan;6(1):59-63 [15723606.001]
  • [Cites] Pharmacogenomics. 2005 Apr;6(3):303-10 [16013961.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):867-75 [16327765.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1109-18 [16809075.001]
  • [Cites] Br J Haematol. 2007 Jun;137(6):513-29 [17539774.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9758-63 [17537913.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2128-36 [17673902.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3374-88 [10550131.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):860-3 [10597212.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):13-23 [10848777.001]
  • [Cites] Blood. 2001 Feb 1;97(3):829-30 [11227095.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1065-74 [16815104.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8975-9 [16982737.001]
  • [Cites] Am J Hum Genet. 2006 Nov;79(5):779-91 [17033956.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31590-5 [11406628.001]
  • (PMID = 18509329.001).
  • [ISSN] 1532-6535
  • [Journal-full-title] Clinical pharmacology and therapeutics
  • [ISO-abbreviation] Clin. Pharmacol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA021765-259006; United States / NIGMS NIH HHS / GM / GM061374-08; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / P30 CA021765-259006; United States / NCI NIH HHS / CA / R01 CA051001-09; United States / NIGMS NIH HHS / GM / GM061393-059002; United States / NIGMS NIH HHS / GM / U01 GM061393-059002; United States / NCI NIH HHS / CA / CA 51001; United States / NCI NIH HHS / CA / CA078224-10; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / CA051001-09; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA 78224; United States / NIGMS NIH HHS / GM / U01 GM061374-08; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NIGMS NIH HHS / GM / U01 GM061374; United States / NCI NIH HHS / CA / R01 CA078224-10; United States / NCI NIH HHS / CA / R01 CA051001; United States / NIGMS NIH HHS / GM / U01 GM61374
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 6PLQ3CP4P3 / Etoposide
  • [Number-of-references] 48
  • [Other-IDs] NLM/ NIHMS68319; NLM/ PMC2583166
  •  go-up   go-down


75. Wiemels JL, Zhang Y, Chang J, Zheng S, Metayer C, Zhang L, Smith MT, Ma X, Selvin S, Buffler PA, Wiencke JK: RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia. Leukemia; 2005 Mar;19(3):415-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia.
  • Among the 142 B-cell acute lymphoblastic leukemia (ALL) cases, RAS mutations were more common among Hispanic children (P=0.11) or children born to mothers <30 years (P=0.007).
  • Those with hyperdiploidy at diagnosis (>50 chromosomes) had the highest rates of RAS mutation (P=0.02).
  • [MeSH-major] Genes, ras / genetics. Mutation. Polyploidy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674422.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCHHSTP CDC HHS / PS / PS42 ES04705; United States / NCI NIH HHS / CA / R01 CA89032; United States / NIEHS NIH HHS / ES / R01 ES09137
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


76. Oztürkmen S, Paç A, Senayl A, Polat TB, Cetin II, Bçakç Z, Akyay A, Olcay L: Schistocytic hemolytic anemia owing to central venous catheter in a child with acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2010 Aug;32(6):e233-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Schistocytic hemolytic anemia owing to central venous catheter in a child with acute lymphoblastic leukemia.
  • SUMMARY: A 4-year-old boy with acute lymphoblastic leukemia (ALL) was inserted a central venous catheter into right vena jugularis interna, whereas on BFM-ALL (Protocol 1) therapy.
  • [MeSH-major] Anemia, Hemolytic / etiology. Catheterization, Central Venous / adverse effects. Erythrocytes / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Anemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20505536.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


77. Li QH, DU X, Huang ZL, Luo CW, Zhong LY, Lin W: [Therapeutic effects of chemotherapeutic regimens containing pirarubicin on the treatment of high-risk or refractory and relapsed acute leukemia in adults]. Zhonghua Yi Xue Za Zhi; 2005 May 11;85(17):1195-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic effects of chemotherapeutic regimens containing pirarubicin on the treatment of high-risk or refractory and relapsed acute leukemia in adults].
  • OBJECTIVE: To evaluate the therapeutic effects of chemotherapeutic regimen containing pirarubicin (THP) on the treatment of high-risk or refractory and relapsed acute leukemia (AL) in adults.
  • METHODS: Forty patients with high-risk or refractory and relapsed AL, 26 males and 14 females, aged 33 (14-63) received treatment regimens with THP: TA regimen [THP + cytosine-arabinoside (Ara-C)] for acute myeloid leukemia (AML) and TAOP regimen [THP + Ara-C + vincristine (VCR) + prednisone (Pred)] for acute lymphocytic leukemia (ALL) or biphenotype-AL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029595.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


78. Armstrong EJ, Bhave P, Wong D, Ursell PC, Kaplan L, Yeghiazarians Y, Ai WZ: Left ventricular rupture due to HIV-associated T-cell lymphoma. Tex Heart Inst J; 2010;37(4):457-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left ventricular rupture due to HIV-associated T-cell lymphoma.
  • Patients with lymphoma can develop cardiac involvement that includes malignant pericardial effusions and myocardial infiltration, but extensive myocardial invasion by tumor with resultant rupture has been reported only rarely.
  • We report a case of a patient with human immunodeficiency virus and T-cell lymphoma who presented with signs and symptoms that were suggestive of a non-ST-elevation myocardial infarction.
  • Autopsy revealed transmural infiltration of the myocardium with lymphoma and resultant rupture of the left ventricular free wall.
  • To our knowledge, this is the 1st reported case of left ventricular free-wall rupture due to transmural infiltration by human-immunodeficiency-virus-associated peripheral T-cell lymphoma.We conclude that noncoronary causes of chest pain, including direct myocardial infiltration, should be considered in immunocompromised patients with lymphoma.

  • Genetic Alliance. consumer health - HIV.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1369-77 [14523146.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):944-51 [7037154.001]
  • [Cites] Eur Heart J. 1987 May;8(5):549-52 [3609049.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Mar;19(3):365-8 [11251283.001]
  • [Cites] Ann Hematol. 2005 Aug;84(8):498-505 [15782345.001]
  • [Cites] Int J Cardiol. 2007 Apr 25;117(2):e84-5 [17331600.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):1008-11 [18464123.001]
  • [Cites] Ann Hematol. 1998 Jul-Aug;77(1-2):75-8 [9760158.001]
  • (PMID = 20844622.001).
  • [ISSN] 1526-6702
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA094143
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2929872
  • [Keywords] NOTNLM ; Acute coronary syndromes / HIV infections/complications / heart neoplasms/secondary / heart rupture / lymphatic metastasis / lymphoma, AIDS-related / lymphoma, T-cell/pathology / myocardium/pathology / neoplasm invasiveness / pericardium/pathology
  •  go-up   go-down


79. Kobayashi K, Kami M, Murashige N, Kusumi E, Kishi Y, Hamaki T, Hori A, Matsumura T, Yuji K, Masuo S, Mori S, Miyakoshi S, Tanosaki R, Mitamura T, Takaue Y, Taniguchi S, Tokyo SCT Consortium Institution: Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors. Br J Haematol; 2005 Jun;129(6):795-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of patients with acute leukaemia who relapsed after reduced-intensity stem cell transplantation from HLA-identical or one antigen-mismatched related donors.
  • We reviewed the medical records of 19 patients with acute leukaemia [acute myeloid leukaemia (AML), 16; acute lymphoblastic leukaemia (ALL), 3] who relapsed after RIST from related donors using purine-analogue-based regimens.
  • [MeSH-major] HLA Antigens / analysis. Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Cause of Death. Female. Graft vs Host Disease / etiology. Histocompatibility Testing. Humans. Male. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953007.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


80. Goldstone AH: Transplantations in adult acute lymphoblastic leukemia--grounds for optimism? Clin Lymphoma Myeloma; 2009;9 Suppl 3:S211-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantations in adult acute lymphoblastic leukemia--grounds for optimism?
  • The large MRC/ECOG Adult Acute Lymphoblastic Leukemia Study establishes the value of sibling donor allogeneic transplantation in patients with standard risk, demonstrating superior outcome to conventional chemotherapy.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Medical Oncology / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778843.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 6
  •  go-up   go-down


81. Chan SM, Weng AP, Tibshirani R, Aster JC, Utz PJ: Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood; 2007 Jul 1;110(1):278-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.
  • Constitutive Notch activation is required for the proliferation of a subgroup of T-cell acute lymphoblastic leukemia (T-ALL).
  • [MeSH-major] Amyloid Precursor Protein Secretases / physiology. Leukemia-Lymphoma, Adult T-Cell / metabolism. Protein Kinases / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Receptors, Notch / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2000 Feb 1;19(3):434-44 [10654941.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):881-8 [16056227.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Science. 2001 Nov 30;294(5548):1942-5 [11729323.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3788-93 [11891328.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] EMBO Rep. 2003 Nov;4(11):1067-72 [14566327.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):343-8 [14667501.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):209-20 [16354692.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1936-40 [16449385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1941-6 [16449386.001]
  • [Cites] Cell. 2006 Feb 10;124(3):471-84 [16469695.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2223-33 [16291593.001]
  • [Cites] Cell. 2006 Mar 10;124(5):973-83 [16530044.001]
  • [Cites] Blood. 2006 May 15;107(10):4115-21 [16449526.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9262-7 [16751266.001]
  • [Cites] BMC Bioinformatics. 2006;7:192 [16600027.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):729-34 [16915295.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8022-31 [16954387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(1):200-16 [14673156.001]
  • [Cites] J Biol Chem. 2004 Jan 23;279(4):2937-44 [14583609.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):909-18 [14990647.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3151-71 [15094765.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):48-54 [15108805.001]
  • [Cites] Nat Med. 2004 May;10(5):484-6 [15098029.001]
  • [Cites] Genes Dev. 2004 Aug 15;18(16):1926-45 [15314020.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Cell Biol. 2004 Oct 25;167(2):215-21 [15492044.001]
  • [Cites] Adv Enzyme Regul. 1984;22:27-55 [6382953.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] J Biol Chem. 1998 Jul 24;273(30):18984-91 [9668078.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Biochemistry. 1999 Aug 10;38(32):10344-51 [10441128.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1390-6 [15558056.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):992-1000 [15592506.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1098-101 [15718470.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):605-11 [15931213.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3337-48 [10880446.001]
  • (PMID = 17363738.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MAML1 protein, human; 0 / MYC protein, human; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptors, Notch; 0 / Trans-Activators; 0 / Transcription Factors; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 3.4.- / Amyloid Precursor Protein Secretases
  • [Other-IDs] NLM/ PMC1896117
  •  go-up   go-down


82. Gez S, Crossett B, Christopherson RI: Differentially expressed cytosolic proteins in human leukemia and lymphoma cell lines correlate with lineages and functions. Biochim Biophys Acta; 2007 Sep;1774(9):1173-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentially expressed cytosolic proteins in human leukemia and lymphoma cell lines correlate with lineages and functions.
  • Identification of cytosolic proteins differentially expressed between types of leukemia and lymphoma may provide a molecular basis for classification and understanding their cellular properties.
  • Two-dimensional fluorescence difference gel electrophoresis (DIGE) and mass spectrometry have been used to identify proteins that are differentially expressed in cytosolic extracts from four human leukemia and lymphoma cell lines: HL-60 (acute promyelocytic leukemia), MEC1 (B-cell chronic lymphocytic leukemia), CCRF-CEM (T-cell acute lymphoblastic leukemia) and Raji (B-cell Burkitt's lymphoma).
  • [MeSH-major] Cytosol / metabolism. Leukemia / metabolism. Lymphoma / metabolism. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698427.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / Neoplasm Proteins; 0 / ezrin; EC 4.2.1.11 / Phosphopyruvate Hydratase; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
  •  go-up   go-down


83. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol; 2005 Oct 1;23(28):7013-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
  • PURPOSE: To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL).
  • Five patients died from acute toxicity.
  • Four patients developed treatment-related myelodysplasia/acute myelogenous leukemia, and three patients died while in remission from MCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Mantle-Cell / drug therapy

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Feb 1;24(4):724
  • (PMID = 16145068.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


84. Reid BA, Allan C, McIntosh JH: Investigation of leukaemia and lymphoma AR-DRGs at a Sydney teaching hospital. HIM J; 2005;34(2):34-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of leukaemia and lymphoma AR-DRGs at a Sydney teaching hospital.
  • Using non-blinded methodology, this study checked the coding of acute leukaemia, non-acute leukaemia and lymphoma episodes assigned to the AR-DRGs R60 A, B, C and R61 A, B during the fiscal year 2000-2001 at a Sydney teaching hospital.
  • [MeSH-major] Diagnosis-Related Groups / classification. Forms and Records Control / classification. Leukemia / classification. Lymphoma / classification. Medical Records / classification
  • [MeSH-minor] Acute Disease. Adult. Aged. Australia. Chi-Square Distribution. Comorbidity. Female. Hospitals, Teaching / utilization. Hospitals, Urban / utilization. Humans. Male. Middle Aged. New South Wales. Severity of Illness Index


85. Fujisawa S, Tanioka F, Matsuoka T, Ozawa T, Naito K, Kobayashi M: CD7/CD19 double-positive T-cell acute lymphoblastic leukemia. Int J Hematol; 2006 May;83(4):324-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD7/CD19 double-positive T-cell acute lymphoblastic leukemia.
  • We report a rare case of T-cell acute lymphoblastic leukemia (T-ALL) with an aberrant phenotype.
  • [MeSH-major] Antigens, CD19. Antigens, CD7. Head and Neck Neoplasms / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Pleural Effusion, Malignant / drug therapy


86. Inukai T, Hirose K, Inaba T, Kurosawa H, Hama A, Inada H, Chin M, Nagatoshi Y, Ohtsuka Y, Oda M, Goto H, Endo M, Morimoto A, Imaizumi M, Kawamura N, Miyajima Y, Ohtake M, Miyaji R, Saito M, Tawa A, Yanai F, Goi K, Nakazawa S, Sugita K: Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia; 2007 Feb;21(2):288-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19.
  • To clarify the clinical characteristics, mechanisms of hypercalcemia, response to management for hypercalcemia, incidence of t(17;19) and final outcome of childhood acute lymphoblastic leukemia (ALL) accompanied by hypercalcemia, clinical data of 22 cases of childhood ALL accompanied by hypercalcemia (>12 mg/dl) reported in Japan from 1990 to 2005 were retrospectively analyzed.
  • [MeSH-major] Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 19. DNA-Binding Proteins / genetics. Hypercalcemia / complications. Hypercalcemia / genetics. Oncogene Proteins, Fusion / genetics. Parathyroid Hormone-Related Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics. Translocation, Genetic


87. Cornelissen JJ, van der Holt B, Verhoef GE, van't Veer MB, van Oers MH, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachée P, Verdonck LF, Löwenberg B, Dekker AW, Dutch-Belgian HOVON Cooperative Group: Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. Blood; 2009 Feb 5;113(6):1375-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.
  • While commonly accepted in poor-risk acute lymphoblastic leukemia (ALL), the role of allogeneic hematopoietic stem cell transplantation (allo-SCT) is still disputed in adult patients with standard-risk ALL.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Autologous / methods. Transplantation, Homologous / methods
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Living Donors. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Prospective Studies. Remission Induction. Risk Factors. Siblings. Transplantation Conditioning. Treatment Outcome. Young Adult


88. Pirrotta MT, Bucalossi A, Forconi F, Gozzetti A, Bocchia M, Mazzotta S, Sammassimo S, Lauria F: Massive intravascular hemolysis: a fatal complication of Clostridium perfringens septicemia in a patient with acute lymphoblastic leukemia. Leuk Lymphoma; 2005 May;46(5):793
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive intravascular hemolysis: a fatal complication of Clostridium perfringens septicemia in a patient with acute lymphoblastic leukemia.
  • [MeSH-major] Bacteremia / complications. Clostridium Infections / complications. Clostridium perfringens. Precursor Cell Lymphoblastic Leukemia-Lymphoma / microbiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Lymphoma. 2004 Oct;45(10):2157-9 [15370265.001]
  • (PMID = 16019522.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


89. Owatari S, Uozumi K, Tokunaga M, Tokunaga M, Haraguchi K, Suzuki S, Arima N: Adult T-cell leukemia/lymphoma in a 21-year-old man. Clin Lab Haematol; 2006 Apr;28(2):141-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma in a 21-year-old man.
  • Adult T-cell leukemia/lymphoma (ATL) is malignancy of mature T cells that caused by infection with human T-cell leukemia virus type I (HTLV-I).
  • But, we report here the case of a 21-year-old man having suffered from recurrent stomatititis who has already developed acute-type ATL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630222.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HTLV-I Antibodies
  •  go-up   go-down


90. Shangguan D, Cao ZC, Li Y, Tan W: Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin Chem; 2007 Jun;53(6):1153-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Molecular-level differentiation of neoplastic cells is essential for accurate and early diagnosis, but effective molecular probes for molecular analysis and profiling of neoplastic cells are not yet available.
  • METHODS: We tested 6 cell-SELEX-generated aptamers with equilibrium dissociation constants in the nanomolar to subnanomolar range: sgd5, selected from Toledo cells, a human diffuse large-cell lymphoma cell line (B-cell), and sgc8, sgc3, sgc4, sgd2, and sgd3 from CCRF-CEM cells, a human precursor T cell acute lymphoblastic leukemia (T-ALL) cell line.
  • Aptamers sgc8, sgc3, and sgd3 showed good selectivity toward T-ALL cells and almost no binding to normal hematopoietic cells or lymphoma and myeloma cells.
  • [MeSH-major] Aptamers, Nucleotide. Burkitt Lymphoma / pathology. Leukemia, Myeloid, Acute / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lymphoma / pathology. Multiple Myeloma / pathology
  • [MeSH-minor] Bone Marrow Cells / cytology. DNA Probes. Fluorescein-5-isothiocyanate. Fluorescent Dyes. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. RNA Probes. SELEX Aptamer Technique. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17463173.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide; 0 / DNA Probes; 0 / Fluorescent Dyes; 0 / RNA Probes; I223NX31W9 / Fluorescein-5-isothiocyanate
  •  go-up   go-down


91. Callera F, Lopes CO, Rosa ES, Mulin CC: Adult transitional pre-B acute lymphoblastic leukemia associated with ring chromosome 16. Cancer Genet Cytogenet; 2008 Jun;183(2):131-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult transitional pre-B acute lymphoblastic leukemia associated with ring chromosome 16.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 16. Ring Chromosomes


92. Song MJ, Kim HJ, Ko YH, Kim SH: Discrepant immunophenotypic characteristics between the lymph node and bone marrow in two mixed-phenotype acute leukemia patients. Korean J Lab Med; 2009 Oct;29(5):396-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discrepant immunophenotypic characteristics between the lymph node and bone marrow in two mixed-phenotype acute leukemia patients.
  • The immunophenotypic profile of hematological malignancies is usually consistent among different sites of involvement; this consistency allows reliable diagnosis from peripheral blood, bone marrow, or lymph node, especially in cases of acute leukemia.
  • Although in a minority of lymphoma patients, two or more different populations with discordant immunophenotypes have been described, either at the same or distinct sites.
  • Here, we report two Korean patients with acute leukemia where the results of immunophenotypic analysis of the bone marrow specimen were different from those of immunohistochemical studies of a biopsy sample of a cervical lymph node, particularly with respect to myeloperoxidase and CD3.
  • Therefore, integration of all the relevant results, including those of the bone marrow studies, may be helpful for accurate diagnosis and selecting appropriate treatment modalities.
  • [MeSH-major] Bone Marrow / pathology. Immunophenotyping / methods. Leukemia / diagnosis. Lymph Nodes / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antigens, CD3 / metabolism. Female. Flow Cytometry. Humans. Male. Peroxidase / metabolism. Phenotype

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893347.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD3; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


93. Bohnstedt C, Taskinen M, Zeller B, Björgvinsdóttir H, Hafsteinsdottir S, Schmiegelow K: Poor treatment compliance in children with down syndrome and acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2009 Jan;31(1):79-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor treatment compliance in children with down syndrome and acute lymphoblastic leukemia.
  • [MeSH-major] Down Syndrome / complications. Down Syndrome / drug therapy. Guideline Adherence / statistics & numerical data. Patient Compliance / statistics & numerical data. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Humans. Infant. Male. Methotrexate / administration & dosage. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Physician's Role. Randomized Controlled Trials as Topic. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125098.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


94. Kelly K, Murphy P: Aplastic anaemia preceding acute lymphoblastic leukaemia in an adult with isolated deletion of chromosome 9q. Leuk Res; 2008 Dec;32(12):1936-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aplastic anaemia preceding acute lymphoblastic leukaemia in an adult with isolated deletion of chromosome 9q.
  • Aplastic anaemia (AA) can precede acute lymphoblastic leukaemia (ALL) in 2% of children but this is rarely reported to occur in adults.
  • He recovered spontaneously but represented 2 months later when he was diagnosed with pre-B acute lymphoblastic leukaemia.
  • [MeSH-major] Anemia, Aplastic / complications. Anemia, Aplastic / genetics. Chromosome Deletion. Chromosomes, Human, Pair 9. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18490054.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Zhang Y, Li L, Ma L, Zhou F, Liu L: Maxillofacial mass as the first presentation of acute lymphoblastic leukemia in a nine-year-old girl. Auris Nasus Larynx; 2010 Jun;37(3):377-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maxillofacial mass as the first presentation of acute lymphoblastic leukemia in a nine-year-old girl.
  • [MeSH-major] Maxillofacial Abnormalities / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19854598.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


96. Frankfurt O, Tallman MS: Growth factors in leukemia. J Natl Compr Canc Netw; 2007 Feb;5(2):203-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The role of myeloid growth factors, such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, in the management of acute myeloid and acute lymphoblastic leukemias has been evaluated extensively in multiple clinical trials.
  • Additionally, growth factors, shown to stimulate proliferation and differentiation of leukemia cells in vitro, were evaluated as monotherapy in patients with acute leukemia.
  • However, more recent reports suggested an improved outcome in younger patients with acute myeloid leukemia with normal karyotype.
  • Several anecdotal case reports have shown that growth factor monotherapy can induce a complete remission in patients with acute leukemia.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Leukemia, Myeloid / drug therapy. Neutropenia / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Humans. Remission Induction

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Compr Canc Netw. 2007 Feb;5(2):117 [17366693.001]
  • (PMID = 17335689.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 60
  •  go-up   go-down


97. Tsuchida M, Ohara A, Manabe A, Kumagai M, Shimada H, Kikuchi A, Mori T, Saito M, Akiyama M, Fukushima T, Koike K, Shiobara M, Ogawa C, Kanazawa T, Noguchi Y, Oota S, Okimoto Y, Yabe H, Kajiwara M, Tomizawa D, Ko K, Sugita K, Kaneko T, Maeda M, Inukai T, Goto H, Takahashi H, Isoyama K, Hayashi Y, Hosoya R, Hanada R, Tokyo Children's Cancer Study Group: Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia; 2010 Feb;24(2):383-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999.
  • We report the long-term results of Tokyo Children's Cancer Study Group's studies L84-11, L89-12, L92-13, and L95-14 for 1846 children with acute lymphoblastic leukemia, which were conducted between 1984 and 1999.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cranial Irradiation. Neoplasm Recurrence, Local / therapy. Neoplasms, Second Primary / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033052.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Kigasawa H; Hashiyama M; Migita M; Matsui A; Yoshihawa H; Kawaguchi H; Makimoto A; Hosono A; Takagi K; Morinaga S; Kiyotani C; Shiota Y; Moriwaki K; Mochizuki S; Toyama D; Kato Y; Hoshi Y; Gunji Y; Kashii Y; Morimoto T; Saito M; Fujimura J; Ishimoto K; Isoyama K; Yamamoto M; Hirota T; Koike K; Yanagisawa R; Ishii E; Kinoshita A; Kondo K; Morimoto M; Ishida Y; Ozawa M; Hasegawa D; Kamiya T; Ochiai H; Sato Y; Sakao E; Ito K; Sunami K; Igarashi T; Komori I; Kakuta H; Kato S; Morimoto K; Yabe M; Mizutani S; Nagasawa M; Koana S; Kashiwagi Y; Takita J; Kato KM; Ooki K; Wada E; Kato F; Kojima Y; Mitsui K; Uchino Y; Watanabe A; Fukushima K; Kurosawa H; Hagisawa S; Sato Y; Fukuoka K; Sugita M; Kaku H; Kawamura M; Fukunaga Y; Migita S; Ueda T; Asano K; Sugita K; Goi K; Fugii H; Ikuta K; Yanagimachi M; Yokosuka T; Kai S; Goto A; Tanaka F; Tsuji K; Ebihara Y; Nakadate N; Ishiguro Y; Suzuki T; Nakao S; Sotomatsu M; Paku A; Bessho F; Yoshino H; Ishii M; Genma Y; Kogawa K; Tsuji Y; Imai K; Sawa F
  •  go-up   go-down


98. Seror E, DeVillartay P, Leverger G, Lenoir G: [HHV-6 infection and acute lymphoblastic leukemia in a child]. Arch Pediatr; 2008 Jan;15(1):37-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [HHV-6 infection and acute lymphoblastic leukemia in a child].
  • We report the case of a child who was infected by HHV-6 and who started an acute lymphoblastic leukemia two months later.
  • [MeSH-major] Herpesvirus 6, Human. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Roseolovirus Infections / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162384.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


99. Hidaka H, Yagasaki H, Takahashi Y, Hama A, Nishio N, Tanaka M, Yoshida N, Villalobos IB, Wang Y, Xu Y, Horibe K, Chen S, Kadomatsu K, Kojima S: Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia. Leuk Res; 2007 Aug;31(8):1045-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased midkine gene expression in childhood B-precursor acute lymphoblastic leukemia.
  • However, expression in acute leukemia has not been clarified.
  • We examined MK gene expression using real-time PCR in 94 children with acute leukemia.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Leukemia, B-Cell / genetics. Leukemia, Myeloid / genetics. Neoplasm Proteins / genetics. Nerve Growth Factors / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


100. Chatterton Z, Morenos L, Saffery R, Craig JM, Ashley D, Wong NC: DNA methylation and miRNA expression profiling in childhood B-cell acute lymphoblastic leukemia. Epigenomics; 2010 Oct;2(5):697-708
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation and miRNA expression profiling in childhood B-cell acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is the most common cancer in children in the modern world.
  • [MeSH-major] DNA Methylation / physiology. Epigenesis, Genetic / physiology. High-Throughput Screening Assays / methods. MicroRNAs / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22122053.001).
  • [ISSN] 1750-192X
  • [Journal-full-title] Epigenomics
  • [ISO-abbreviation] Epigenomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down






Advertisement